

Financial news for BMRN dated on 2020-06-10: Why Biomarin's Stock Is Trading Higher Today

Financial news for BMRN dated on 2020-06-10: Biomarin Pharmaceutical shares are trading higher after Bank of America Securities maintained its Buy rating on the stock and raised the price target from \$120 to \$130 per share.

Financial news for BMRN dated on 2020-06-10: B of A Securities Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to \$130

Financial news for BMRN dated on 2020-06-05: The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets \$400M Bid

Financial news for BMRN dated on 2020-06-04: Stocks That Hit 52-Week Highs On Thursday

Financial news for BMRN dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for BMRN dated on 2020-05-31: Biomarin Reports Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

Financial news for BMRN dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for BMRN dated on 2020-05-26: Shares of several healthcare companies are trading higher in sympathy with the overall market as equities rally on coronavirus vaccine hopes as well as a pickup in economic activity as some US states reopen businesses.

Financial news for BMRN dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for BMRN dated on 2020-05-11: BioMarin Announces Plans to Offer \$500M of Convertible Notes

Financial news for BMRN dated on 2020-05-08: 5 Biopharmas Where BofA Would Put Its Money To Work

Financial news for BMRN dated on 2020-05-04: BioMarin Strikes Gene Therapy Partnership Targeting Rare Genetic Cardiomyopathies

Financial news for BMRN dated on 2020-05-04: BioMarin Announces Preclinical Collaboration and License Agreement with DiNAQOR to Develop Gene Therapies for Rare Genetic Cardiomyopathies

Financial news for BMRN dated on 2020-05-01: Shares of several healthcare companies are trading lower as markets dip following recent strength. Markets have sold off as investors weigh recent earnings and amid concerns of renewed US-China trade frictions.

Financial news for BMRN dated on 2020-04-30: SunTrust Robinson Humphrey Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to \$109

Financial news for BMRN dated on 2020-04-30: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to \$128

Financial news for BMRN dated on 2020-04-29: Biomarin Pharmaceutical Q1 EPS \$0.440 Beats \$0.050 Estimate, Sales \$502.100M Beat \$468.770M Estimate

Financial news for BMRN dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for BMRN dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for BMRN dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for BMRN dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for BMRN dated on 2020-04-06: BioMarin Pharma Reports Regulatory Submissions For Marketing Authorization Of Vosoritide To Treat Children With Achondroplasia In Q3 In US, Europe

Financial news for BMRN dated on 2020-03-31: Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has

potentially benefited the sector due to demand for medical supplies, testing and treatment candidates

Financial news for BMRN dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for BMRN dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for BMRN dated on 2020-03-16: Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.

Financial news for BMRN dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for BMRN dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Financial news for BMRN dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for BMRN dated on 2020-03-03: Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to \$125

Financial news for BMRN dated on 2020-03-02: Wedbush Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to \$164

Financial news for BMRN dated on 2020-02-26: Biomarin Sees FY20 Sales \$1.95B-\$2.05B vs \$1.53B Estimate

Financial news for BMRN dated on 2020-02-26: Biomarin Pharmaceutical Q4 EPS \$0.08 Beats \$(0.09) Estimate, Sales \$454.4M Miss \$459.33M Estimate

Financial news for BMRN dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for BMRN dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for BMRN dated on 2020-02-21: Biomarin Pharmaceutical shares are trading higher after the FDA accepted for priority review the company's Biologics License Application for valoctocogene roxaparvovec.

Financial news for BMRN dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for BMRN dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for BMRN dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for BMRN dated on 2020-02-03: BioMarin Announces CFO Succession; Brian R. Mueller To Assume CFO Role

Financial news for BMRN dated on 2020-01-31: Shares of several healthcare companies are trading lower as fears of the coronavirus' potential impact on the global economy intensifies. The death toll continues to rise and the U.K. and Russia confirmed their first cases.

Financial news for BMRN dated on 2020-01-28: Benzinga's Top Upgrades, Downgrades For January 28, 2020

Financial news for BMRN dated on 2020-01-28: BMO Capital Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces \$94 Price Target

Financial news for BMRN dated on 2020-01-26: Barron's Picks And Pans: BioMarin, Caesars, Royal Caribbean And More

Financial news for BMRN dated on 2020-01-24: RBC Capital Upgrades Biomarin

Pharmaceutical to Sector Outperform

Financial news for BMRN dated on 2020-01-13: BioMarin To Begin Clinical Trial With BMN 307 Gene Therapy; Expects To Start Dosing Patients In Phase 1 Trial In Q1 Of 2020

Financial news for BMRN dated on 2020-01-13: BioMarin to Begin Clinical Trial with BMN 307 Gene Therapy

Financial news for BMRN dated on 2020-01-10: Biomarin Pharmaceutical shares are trading higher potentially in anticipation of JPMorgan's Healthcare Conference.

Financial news for BMRN dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for BMRN dated on 2020-01-09: Biomarin Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for BMRN dated on 2020-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2020

Financial news for BMRN dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for BMRN dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for BMRN dated on 2019-12-23: BioMarin Submits Biologics License Application To FDA For Valoctocogene Roxaparvovec To Treat Hemophilia A

Financial news for BMRN dated on 2019-12-23: European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec To Treat Severe Hemophilia A

Financial news for BMRN dated on 2019-12-16: Biomarin Pharmaceuticals shares are trading higher after the company announced positive results for its Phase 3 study of Vosoritide.

Financial news for BMRN dated on 2019-12-16: BioMarin Announces Positive Results From its Phase 3 Study of Vosoritide

Financial news for BMRN dated on 2019-12-10: Invitae Announces Program With BioMarin To Expand Access To Genetic Testing For Skeletal Dysplasias

Financial news for BMRN dated on 2019-12-03: The Gene Therapy Names Moving On The Audentes Buyout Deal

Financial news for BMRN dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for BMRN dated on 2019-11-27: Biomarin Pharmaceutical shares are trading higher after Barclays upgraded the company's stock from Equal-Weight to Overweight and announced a \$98 price target.

Financial news for BMRN dated on 2019-11-27: Benzinga's Top Upgrades, Downgrades For November 27, 2019

Financial news for BMRN dated on 2019-11-27: Barclays Upgrades Biomarin Pharmaceutical to Overweight, Announces \$98 Price Target

Financial news for BMRN dated on 2019-11-21: BioMarin Reports Submission Of Marketing Authorization Application To EMA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A

Financial news for BMRN dated on 2019-11-19: Biomarin Pharmaceutical shares are trading higher. Not seeing any news to justify the price action.

Financial news for BMRN dated on 2019-11-14: BioMarin Sees Vosoritide Phase 3 Topline Results By End Of 2019

Financial news for BMRN dated on 2019-11-14: BioMarin Says Valoctocogene Roxaparvovec On Track For US, EU Regulatory Submission By End Of 2019

Financial news for BMRN dated on 2019-11-14: BioMarin Sees FY20 GAAP EPS Breakeven Or Better

Financial news for BMRN dated on 2019-11-14: BioMarin Offers Update On Clinical Program For Vosoritide In Children With Achondroplasia

Financial news for BMRN dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for BMRN dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Biomarin Pharmaceutical with Buy Rating, Announces \$110 Price Target

Financial news for BMRN dated on 2019-11-06: Biomarin Pharmaceutical Option Alert: Nov 15 \$75 Calls Sweep (5) near the Ask: 1338 @ \$1.801 vs 3126 OI; Ref=\$74.87

Financial news for BMRN dated on 2019-10-30: Citigroup Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to \$95

Financial news for BMRN dated on 2019-10-28: Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to \$108

Financial news for BMRN dated on 2019-10-25: Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$152

Financial news for BMRN dated on 2019-10-24: Barclays Maintains Equal-Weight on Biomarin Pharmaceutical, Lowers Price Target to \$86

Financial news for BMRN dated on 2019-10-24: Nomura Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to \$77

Financial news for BMRN dated on 2019-10-23: Biomarin Pharmaceutical Q3 EPS \$0.30 Beats \$0.07 Estimate, Sales \$461.1M Beat \$454.22M Estimate

Financial news for BMRN dated on 2019-10-23: Biomarin Pharmaceuticals shares are trading higher on anticipation of the release of the company's Q3 earnings scheduled for release today after the close.

Financial news for BMRN dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for BMRN dated on 2019-10-20: The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Financial news for BMRN dated on 2019-10-17: Bank of America Reinstates Buy on Biomarin Pharmaceutical, Announces \$90 Price Target

Financial news for BMRN dated on 2019-10-03: The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

Financial news for BMRN dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for BMRN dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for BMRN dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for BMRN dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for BMRN dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for BMRN dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for BMRN dated on 2019-09-27: Biomarin Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.

Financial news for BMRN dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for BMRN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for BMRN dated on 2019-09-26: BioMarin Submits Clinical Trial Application In UK For Investigational Gene Therapy For PKU

Financial news for BMRN dated on 2019-09-24: Shares of many pharma/therapeutics

stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for BMRN dated on 2019-09-10: Biomarin Pharmaceutical shares are trading higher after the company announced it would participated at the Morgan Stanley 17th Annual Global Healthcare Conference.

Financial news for BMRN dated on 2019-08-22: Biomarin Pharmaceutical Option Alert: Sep 20 \$85 Calls Sweep (5) near the Ask: 832 @ \$0.858 vs 1886 OI; Ref=\$77.95

Financial news for BMRN dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for BMRN dated on 2019-08-16: Biomarin Pharmaceutical Option Alert: Sep 20 \$85 Calls Sweep (39) near the Ask: 501 @ \$0.65 vs 492 OI; Ref=\$75.65

Financial news for BMRN dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for BMRN dated on 2019-08-15: Stocks That Hit 52-Week Lows On Thursday

Financial news for BMRN dated on 2019-08-15: The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

Financial news for BMRN dated on 2019-08-14: Stocks That Hit 52-Week Lows On Wednesday

Financial news for BMRN dated on 2019-08-13: Stocks That Hit 52-Week Lows On Tuesday

Financial news for BMRN dated on 2019-08-13: The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novellion Delays Quarterly Results

Financial news for BMRN dated on 2019-08-12: Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.

Financial news for BMRN dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for BMRN dated on 2019-08-02: 40 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for BMRN dated on 2019-08-01: Biomarin Pharmaceutical Q2 EPS \$(0.21) May Not Compare To \$(0.1) Estimate, Sales \$387.8M Miss \$414.4M Estimate

Financial news for BMRN dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for BMRN dated on 2019-07-30: New 52-Week Lows for Tuesday Morning

Financial news for BMRN dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for BMRN dated on 2019-07-19: Biomarin Pharmaceutical Option Alert: Aug 16 \$95 Calls at the Ask: 1981 @ \$0.5 vs 297 OI; Earnings 8/1 After Close Ref=\$82.2101

Financial news for BMRN dated on 2019-07-19: Biomarin Pharmaceutical Option Alert: Aug 16 \$90 Calls Sweep (34) near the Ask: 514 @ \$0.851 vs 529 OI; Earnings 8/1 After Close Ref=\$82.15

Financial news for BMRN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for BMRN dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for BMRN dated on 2019-07-08: BioMarin Plans Regulatory Submissions For Marketing Authorization Of Valoctocogene Roxaparovvec To Treat Severe Hemophilia A In 4Q 2019 In US And Europe

Financial news for BMRN dated on 2019-06-21: BioMarin Receives \$15M In Milestone Payments From Pfizer For TALZENNA For Metastatic Breast Cancer Patients With An

Inherited BRCA Mutation

Financial news for BMRN dated on 2019-06-18: BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia

Financial news for BMRN dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for BMRN dated on 2019-06-04: BioMarin Receives Approval Of Vimizim In China For Treatment Of Morquio A Syndrome

Financial news for BMRN dated on 2019-05-29: A Look At Benzinga Pro's Most-Searched Tickers For May 29, 2019

Financial news for BMRN dated on 2019-05-29: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 29, 2019

Financial news for BMRN dated on 2019-05-28: Benzinga Pro's Top Most Searched Tickers For May 28, 2019

Financial news for BMRN dated on 2019-05-28: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 28, 2019

Financial news for BMRN dated on 2019-05-28: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BMRN dated on 2019-05-28: BioMarin Announces Phase 3 Cohort Of Valoctocogene Roxaparvovec, Gene Therapy Study In Severe Hemophilia A Met Pre-Specified Criteria For Regulatory Submissions In US and Europe

Financial news for BMRN dated on 2019-05-28: BioMarin 3-Year Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A Shows 'Substantial Reduction In Excess Of 92% In Mean Bleed Rate Requiring Factor VIII Infusions'

Financial news for BMRN dated on 2019-05-15: BioMarin shares trading higher on no fundamental news. The stock rebounded from just below the \$80 level on Friday and tested that support level again on Monday.

Financial news for BMRN dated on 2019-05-02: 5 Biotech Stocks With Near-Term Catalysts Ahead

Financial news for BMRN dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for BMRN dated on 2019-04-26: Wedbush Maintains Outperform on BioMarin Pharmaceutical Inc. - Common Stock, Raises Price Target to \$128

Financial news for BMRN dated on 2019-04-26: The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

Financial news for BMRN dated on 2019-04-25: BioMarin Sees FY19 Sales \$1.68B-\$1.75B vs \$1.69B Estimate, Adj. Net Income \$130M-\$170M

Financial news for BMRN dated on 2019-04-25: Biomarin Pharmaceutical Q1 GAAP EPS \$(0.32) May Not Compare To \$(0.19) Estimate, Sales \$400.7M Beat \$391.54M Estimate

Financial news for BMRN dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for BMRN dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for BMRN dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for BMRN dated on 2019-04-10: Get In On Genomics With This New ETF

Financial news for BMRN dated on 2019-04-09: Raymond James Reinstates Outperform on Biomarin Pharmaceutical, Announces \$110 Price Target

Financial news for BMRN dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for BMRN dated on 2019-03-01: BioMarin Reports Received Positive CHMP Opinion For Palynziq For Treatment Of Patients With Phenylketonuria Aged 16 and Older

Financial news for BMRN dated on 2019-02-25: Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Financial news for BMRN dated on 2019-02-25: Biomarin Pharma shares are trading higher in sympathy to Spark Therapeutics which was acquired by Roche earlier Monday.

Financial news for BMRN dated on 2019-02-22: BioMarin Pharma shares are trading lower after the company reported Q4 sales of \$353 million versus the \$380 million analyst estimate.

Financial news for BMRN dated on 2019-02-22: The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Financial news for BMRN dated on 2019-02-21: Biomarin Pharmaceutical Q4 GAAP EPS \$(0.03), Adj. Net Loss \$10.8M, Sales \$353.214M Miss \$379.79M Estimate

Financial news for BMRN dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for BMRN dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for BMRN dated on 2019-02-07: Biomarin Announces Ongoing Study Demonstrates Durable Treatment Benefit From Brineura For 3 Years; Reduced Rate Of Decline Maintained In Children With CLN2 Disease

Financial news for BMRN dated on 2019-01-09: Biomarin Pharmaceuticals shares are trading down after the company cut FY18 adj. net income guidance.

Financial news for BMRN dated on 2019-01-09: The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brain Cancer Drug Study

Financial news for BMRN dated on 2019-01-08: BioMarin Cuts FY18 Adj. Net Income Guidance From \$100M-\$140M To \$90M-\$105M

Financial news for BMRN dated on 2019-01-08: UPDATE: BioMarin Reaffirms FY18 Total Sales Guidance \$1.47B-\$1.53B vs \$1.52B Estimate

Financial news for BMRN dated on 2019-01-08: BioMarin 8-K Shows Slides For JP Morgan Healthcare Conference Presentation

Financial news for BMRN dated on 2019-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2019

Financial news for BMRN dated on 2019-01-02: Raymond James Downgrades Biomarin Pharmaceutical to Market Perform

Financial news for BMRN dated on 2018-12-18: Shares of Biomarin Pharmaceuticals are trading lower after Guggenheim initiated coverage on the stock with a Neutral rating.

Financial news for BMRN dated on 2018-12-18: Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

Financial news for BMRN dated on 2018-12-18: Guggenheim Initiates Coverage On Biomarin Pharmaceutical with Neutral Rating

Financial news for BMRN dated on 2018-12-14: Oppenheimer Initiates Coverage On Biomarin Pharmaceutical with Perform Rating

Financial news for BMRN dated on 2018-12-10: 5 Biotech Companies To Keep On Your M&A Watchlist For 2019

Financial news for BMRN dated on 2018-11-07: BioMarin Says PKU Gene Therapy Planned For 2H 2019

Financial news for BMRN dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for BMRN dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for BMRN dated on 2018-10-25: Biomarin Pharmaceutical Q3 GAAP EPS \$(0.07) Beats \$(0.22) Estimate, Sales \$391.706M Beat \$367.09M Estimate

Financial news for BMRN dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes

Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for BMRN dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for BMRN dated on 2018-10-16: BioMarin Receives \$15M Milestone Payments From Pfizer For TalzennaFor Metastatic Breast Cancer Patients; Milestones Triggered By FDA Approval Of Talzenna

Financial news for BMRN dated on 2018-10-05: 3 Screens That Hint At Which Stocks May Outperform In Q4

Financial news for BMRN dated on 2018-10-01: Benzinga's Top Upgrades, Downgrades For October 1, 2018

Financial news for BMRN dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Biomarin Pharmaceutical with Overweight Rating, Announces \$126 Price Target

Financial news for BMRN dated on 2018-08-15: Express Scripts in Talks With Biomarin Pharmaceutical, Spark Therapeutics, Bluebird Bio to have Specialty Pharmaceutical Business Exclusively Distribute Their New Hemophilia Treatments

Financial news for BMRN dated on 2018-08-09: Citigroup Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to \$120

Financial news for BMRN dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for BMRN dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for BMRN dated on 2018-08-06: Barclays Maintains Equal-Weight on Biomarin Pharmaceutical, Raises Price Target to \$98

Financial news for BMRN dated on 2018-08-06: Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$120

Financial news for BMRN dated on 2018-08-03: Stifel Nicolaus Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to \$109

Financial news for BMRN dated on 2018-08-03: Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to \$115

Financial news for BMRN dated on 2018-08-02: Biomarin Pharmaceutical Q2 EPS \$(0.09) Beats \$(0.20) Estimate, Sales \$372.845M Beat \$357.5M Estimate

Financial news for BMRN dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for BMRN dated on 2018-07-31: Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to \$113

Financial news for BMRN dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for BMRN dated on 2018-07-09: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$122

Financial news for BMRN dated on 2018-06-14: BioMarin Doses Initial Participant in Phase 2 Study of Vosoritide

Financial news for BMRN dated on 2018-06-07: BioMarin Receives \$20M Milestone Payments From Pfizer For Talazoparib

Financial news for BMRN dated on 2018-05-31: JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to \$133

Financial news for BMRN dated on 2018-05-29: 7 Biggest Price Target Changes For Tuesday

Financial news for BMRN dated on 2018-05-29: Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$115

Financial news for BMRN dated on 2018-05-25: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$120

Financial news for BMRN dated on 2018-05-25: 7 Biggest Price Target Changes For Friday

Financial news for BMRN dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for BMRN dated on 2018-05-25: Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to \$105

Financial news for BMRN dated on 2018-05-24: BioMarin Receives Standard FDA Approval for Palynziq

Financial news for BMRN dated on 2018-05-22: UPDATE: FDA Is Planning Easier Approval For Experimental Gene Therapies

Financial news for BMRN dated on 2018-05-22: Watching Gene Therapy Stocks Amid Report FDA Could Allow Gene Therapy Approval On Surrogate Endpoints

Financial news for BMRN dated on 2018-05-22: Hearing Citi Out Defending BioMarin's Valoctocogene Roxaparvovec Data Released This Morning, Unconfirmed

Financial news for BMRN dated on 2018-05-22: Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

Financial news for BMRN dated on 2018-05-22: BioMarin Provides 2 Years Of Clinical Data In 6el3 vg/kg Dose From Ongoing Phase 1/2 Study In Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A At World Federation Of Hemophilia 2018 World Congress

Financial news for BMRN dated on 2018-05-21: The Week Ahead: Target, Best Buy Help Close Out Earnings Season

Financial news for BMRN dated on 2018-05-21: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for BMRN dated on 2018-05-16: Benzinga's Top Upgrades, Downgrades For May 16, 2018

Financial news for BMRN dated on 2018-05-16: Canaccord Genuity Initiates Coverage On Biomarin Pharmaceutical with Buy Rating, Announces \$101 Price Target

Financial news for BMRN dated on 2018-05-15: BioMarin Reports First Patient Dosed In Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy In severe Hemophilia A Patients With Pre-Existing AAV5 Antibodies

Financial news for BMRN dated on 2018-05-10: BioMarin Shares Unaffected As Traders Circulate Word CEO Will Be On CNBC's 'Mad Money' Thurs. Evening

Financial news for BMRN dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for BMRN dated on 2018-04-30: Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to \$113.00

Financial news for BMRN dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for BMRN dated on 2018-04-25: BioMarin Sees FY18 Adj. Net Income \$100M-\$140M, Sales \$1.47B-\$1.53B vs \$1.49B Est.

Financial news for BMRN dated on 2018-04-25: BioMarin Pharma Q1 EPS \$(0.26) Misses \$(0.18) Est., Sales \$373.4M Beats \$348.57M Est.

Financial news for BMRN dated on 2018-04-25: Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Financial news for BMRN dated on 2018-04-24: BioMarin Highlights Updated Results From Study Evaluating Efficacy, Safety Of Brineura In Children With CLN2 Disease Published In NEJM; Showed '...patients treated with Brineura experienced a slower rate of decline in motor and language function...'

Financial news for BMRN dated on 2018-04-24: Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Financial news for BMRN dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for BMRN dated on 2018-04-20: BioMarin Shares Down 3.2% From Session High

Financial news for BMRN dated on 2018-03-28: BioMarin Reports EMA Accepted Co.'s Marketing Application For Pegvaliase MAA For Treatment Of PKU

Financial news for BMRN dated on 2018-03-02: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to \$116.00

Financial news for BMRN dated on 2018-02-23: Why Leerink Adjusted Upside Expectations For 3 Biotechs

Financial news for BMRN dated on 2018-02-23: Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Lowers price target to \$112.00

Financial news for BMRN dated on 2018-02-23: Stifel Nicolaus Maintains Buy on Biomarin Pharmaceutical, Lowers price target to \$102.00

Financial news for BMRN dated on 2018-02-23: Leerink Swann Maintains Outperform on Biomarin Pharmaceutical, Lowers price target to \$132.00

Financial news for BMRN dated on 2018-02-23: BMO Capital Maintains Outperform on Biomarin Pharmaceutical, Raises price target to \$125.00

Financial news for BMRN dated on 2018-02-23: Deutsche Bank Maintains Buy on Biomarin Pharmaceutical, Raises price target to \$124.00

Financial news for BMRN dated on 2018-02-22: BioMarin Sees FY18 Sales \$1.47-\$1.53B vs \$1.48B Est.

Financial news for BMRN dated on 2018-02-22: BioMarin Reports Q4 EPS \$(0.30) vs \$(0.23) Est., Sales \$358.3M vs \$351M Est.

Financial news for BMRN dated on 2018-02-22: Biomarin Pharmaceutical Q4 Earnings Outlook

Financial news for BMRN dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for BMRN dated on 2018-02-07: BioMarin Reports Interim Phase 1/2 Data Of BMN 250 For Treatment Of MPS IIIB: 'Normalization of biomarker and liver size; stabilization of early cognitive effects suggested in preliminary data'

Financial news for BMRN dated on 2018-01-30: CNBC's Meg Tirrell Tweets 'Spoke w \$PFE mgmt team after the call...about gene therapy safety concerns...pointed out none with \$PFE \$AVXS \$ONCE \$BMRN studies. Said...surprised Wilson & \$SLDB "didn't have any way to resolve" concerns [properly]'

Financial news for BMRN dated on 2018-01-24: Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%

Financial news for BMRN dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for BMRN dated on 2018-01-03: Wall Street Reacts To Spark Therapeutics' \$850K Genetic Blindness Treatment

Financial news for BMRN dated on 2017-12-22: BioMarin Announces a PDUFA Extension for Pegvaliase Biologics License Application Until May 28

Financial news for BMRN dated on 2017-12-19: BioMarin Doses First Patient In GENER8-1 Phase 3 Study Of Valoctocogene Roxaparvovec

Financial news for BMRN dated on 2017-12-15: UPDATE: Goldman Added Alnylam and Biomarin To 2018 Conviction Buy List Earlier This Morning, Hologic Was Added To Conviction Buy List On 12/7 For 2018

Financial news for BMRN dated on 2017-12-15: Goldman Adds Biomarin, Alnylam To Conviction Buy List For 2018; Earlier Post Said That Hologic Was Added To Conviction Buy List For 2018, That Note Was Updated Today, But Was Originally Published 12/7

Financial news for BMRN dated on 2017-12-14: Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Financial news for BMRN dated on 2017-12-14: Benzinga's Top Upgrades, Downgrades For December 14, 2017

Financial news for BMRN dated on 2017-12-14: Wedbush Upgrades Biomarin Pharmaceutical to Outperform

Financial news for BMRN dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for BMRN dated on 2017-12-11: 11 Biotech Stocks Moving From ASH 2017

Financial news for BMRN dated on 2017-12-11: Biomarin Option Alert: Fri \$80 Calls Sweep (38) at the Ask: 859 @ \$8.0 vs 201 OI; Ref=\$87.65

Financial news for BMRN dated on 2017-12-11: BioMarin Shares Up 6.38% After Reporting Saturday From ASH Data For Valoctocogene Roxaparvovec, Co. Expects To Begin Enrolling Patients In Phase 3 GENE8 Studies This Month

Financial news for BMRN dated on 2017-12-09: BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at #ASH2017

Financial news for BMRN dated on 2017-11-27: BioMarin Sells Second Priority Review Voucher from the FDA for \$125 Million

Financial news for BMRN dated on 2017-11-06: 9 Notable Biotechs Presenting At This Year's ASH Meeting

Financial news for BMRN dated on 2017-10-26: BioMarin Narrows FY17 Sales Outlook From \$1.285B-\$1.335B To \$1.29B-\$1.32B vs \$1.31B Est.

Financial news for BMRN dated on 2017-10-26: BioMarin Reports Q3 GAAP EPS \$(0.07) May Not Compare To \$(0.12) Est., Sales \$334.1M vs \$349.6M Est.

Financial news for BMRN dated on 2017-10-26: BioMarin Reports FDA Granted Breakthrough Therapy Designation For Co.'s Valoctocogene Roxaparvovec

Financial news for BMRN dated on 2017-10-18: Biomarin Shares Down 6.6% As Co. Says At Investor Day That Slowing Of Govt. Purchases In Brazil May Impact Revenue Guidance

Financial news for BMRN dated on 2017-10-03: BioMarin Names Robert J. Hombach, Former Baxalta CFO and COO, To Board Of Directors

Financial news for BMRN dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for BMRN dated on 2017-09-14: UPDATE: Biomarin Says FDA Has Requested Additional CMC Information For Pegvaliase, Which Co. Expects Will Extend 2/28/18 PDUFA Date By 3 Months

Financial news for BMRN dated on 2017-09-14: BioMarin Reports FDA Is Not Currently Planning Advisory Panel Meeting For Co.'s Pegvaliase BLA Regulatory Review Process

Financial news for BMRN dated on 2017-09-14: PiperJaffray Assumes Biomarin Pharmaceutical to Overweight

Financial news for BMRN dated on 2017-09-06: BioMarin Offers Interim Data Of Phase 1/2 Study Of BMN 250 For Treatment Of BPS IIIB: 'Preliminary biomarker and liver size data show marked decreases; early cognitive effects encouraging, pending more mature data'

Financial news for BMRN dated on 2017-08-29: Biomarin FDA Accepts BioMarin's Pegvaliase Biologics License Application and Grants Priority Review Designation

Financial news for BMRN dated on 2017-08-17: Benzinga's Top Upgrades, Downgrades For August 17, 2017

Financial news for BMRN dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating

Financial news for BMRN dated on 2017-08-02: BioMarin Reports Q2 GAAP EPS \$(0.21) May Not Compare To \$(0.21) Est., Sales \$317.4M vs \$309M Est.

Financial news for BMRN dated on 2017-08-02: BioMarin Reports Plans To Progress Both 6e13vg/kg, 4e13 vg/kg Doses Of BMN 270

Financial news for BMRN dated on 2017-07-27: Bernstein Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces \$89.00 Price Target

Financial news for BMRN dated on 2017-07-27: Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National

Financial news for BMRN dated on 2017-07-26: BioMarin Shares Spike ~\$0.50 Over Last Min. As Traders Circulate Chatter In Name

Financial news for BMRN dated on 2017-07-20: Following Q2 Beat, Sarepta Has A Key Catalyst Coming In Q4

Financial news for BMRN dated on 2017-07-18: UPDATE: Sarepta Will Make 1-Time Payment

Of \$35M To BioMarin, Certain Added Regulatory, Commercial Milestone Payments For Exons 51, 45, 53, Possibly On Future Exon-Skipping Products

Financial news for BMRN dated on 2017-07-18: Sarepta, BioMarin Report Execution Of Global Settlement, License Deal Resolving Exon Skipping Patent Litigation

Financial news for BMRN dated on 2017-07-12: Analyst: Shire Shares Should Rebound, But Sustained Rally Unlikely

Financial news for BMRN dated on 2017-07-11: BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year

Financial news for BMRN dated on 2017-07-07: A Barrage Of Biotech Updates Expected At ISTH Meeting

Financial news for BMRN dated on 2017-06-30: BioMarin Submits Pegvaliase Biologics License Application To FDA

Financial news for BMRN dated on 2017-06-06: Companies Holding Shareholder Meetings Today Include: Acacia Research, BioMarin Pharmaceutical, AMC Networks, Live Nation Entertainment, Kate Spade, IMAX, GoPro, Netflix, Sarepta, Salesforce, TJX Companies, And Tesla

Financial news for BMRN dated on 2017-06-01: BioMarin Reports EC Approved Brineura for Treatment of CLN2 Disease

Financial news for BMRN dated on 2017-05-04: BioMarin Sees FY17 Sales \$1.25-\$1.3B vs \$1.27B Est.

Financial news for BMRN dated on 2017-05-04: BioMarin Reports Q1 EPS \$(0.09) vs \$(0.29) Est., Sales \$303.74M vs \$288M Est.

Financial news for BMRN dated on 2017-04-27: BioMarin Issues Release Confirming FDA Approval of Brineura for Treatment of CLN2 Disease

Financial news for BMRN dated on 2017-04-27: Biomarin's Brineura (cerliponase alfa) Approved By FDA For Treatment For A Specific Form Of Batten Disease

Financial news for BMRN dated on 2017-04-27: Biomarin Cerliponase Alfa PDUFA Date Today

Financial news for BMRN dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for BMRN dated on 2017-04-24: Adam Feuerstein Tweets: \$BMRN Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action
thestreet.com/story/14098902... via @TheStreet

Financial news for BMRN dated on 2017-04-21: EMA Recommends Approval Of Biomarin's Neuronal Ceroid Lipofuscinosis Drug

Financial news for BMRN dated on 2017-04-13: BioMarin Reports Kuvan Patent Challenge Settlement: BioMarin Will Grant Par Non-Exclusive License to Patents, Allowing Par to Market Generic Version

Financial news for BMRN dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for BMRN dated on 2017-04-05: Feuerstein Throws BioMarin Into Gilead Takeover Speculation

Financial news for BMRN dated on 2017-04-05: Feuerstein on Possibilities of Gilead Takeover Interest: Notes A Lot of Sources Have Talked About TESARO as Target, But Feels BioMarin is a Co. Which Has Better Chance to Move the Needle at Gilead

Financial news for BMRN dated on 2017-04-05: Feuerstein on Possibilities of Gilead Takeover Interest: Likes BioMarin as a Target

Financial news for BMRN dated on 2017-03-30: Benzinga's Top Upgrades, Downgrades For March 30, 2017

Financial news for BMRN dated on 2017-03-30: UBS Initiates Coverage On Biomarin Pharmaceutical With Neutral, Announces \$92 Price Target

Financial news for BMRN dated on 2017-03-02: Nomura Initiates Coverage On Biomarin Pharmaceutical at Neutral

Financial news for BMRN dated on 2017-02-27: Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Financial news for BMRN dated on 2017-02-23: BioMarin Sees FY17 Sales \$1.25-\$1.3B vs. \$1.31B Est.

Financial news for BMRN dated on 2017-02-23: BioMarin Reports Q4 GAAP EPS \$(0.53) vs. \$(0.38) Est., Sales \$300M vs. \$295M

Financial news for BMRN dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for BMRN dated on 2017-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2017

Financial news for BMRN dated on 2017-02-07: Morgan Stanley Initiates Coverage On Biomarin Pharmaceutical At Overweight, Announces \$110 Price Target

Financial news for BMRN dated on 2017-02-01: BioMarin Reports Received Access to PRIME Regulatory Support from EMA for BMN 270 in Hemophilia A

Financial news for BMRN dated on 2017-01-23: BioMarin's Upcoming Catalysts Named By Credit Suisse

Financial news for BMRN dated on 2017-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2017

Financial news for BMRN dated on 2017-01-23: Credit Suisse Assumes Biomarin Pharmaceutical at Outperform, Lowers Target to \$107.00

Financial news for BMRN dated on 2017-01-10: Sarepta Soars Following Encouraging Exondys 51 News

Financial news for BMRN dated on 2017-01-08: BioMarin Announces Update to Positive Interim Results of Open-label Phase 1/2 Study of BMN 270 as Treatment for Severe Hemophilia A at #JPM17

Financial news for BMRN dated on 2017-01-05: Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'

Financial news for BMRN dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for BMRN dated on 2016-12-21: Biomarin Spiking Higher on Volume

Financial news for BMRN dated on 2016-12-12: BioMarin Enrolls First Patent in Phase Vosoritide Trial

Financial news for BMRN dated on 2016-12-09: Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt

Financial news for BMRN dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for BMRN dated on 2016-11-29: 7 Biggest Price Target Changes For Tuesday

Financial news for BMRN dated on 2016-11-29: Barclays Downgrades Biomarin Pharmaceutical to Equal-Weight, Lowers Target to \$105.00

Financial news for BMRN dated on 2016-11-17: BioMarin Tells Bloomberg They Will Not Present At ASH Conf., Plan To Update BMN 270 In January

Financial news for BMRN dated on 2016-11-17: BioMarin Spikes to High of \$92.30 on Volume

Financial news for BMRN dated on 2016-11-16: Jefferies London Healthcare Conference Taking Place Today

Financial news for BMRN dated on 2016-11-07: Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself

Financial news for BMRN dated on 2016-11-07: Benzinga's Top Downgrades

Financial news for BMRN dated on 2016-11-07: PiperJaffray Downgrades BioMarin Pharmaceutical Inc. - Common Stock to Neutral

Financial news for BMRN dated on 2016-11-04: Biomarin Spokesperson Tells Benzinga They Have 'No Comment' Regarding The Company's Stock Move Today

Financial news for BMRN dated on 2016-11-04: Alexion, BioMarin Spike Higher as Traders Circulate Unconfirmed Report Alexion has Cancelled Out of CS Conference

Financial news for BMRN dated on 2016-11-04: BioMarin Spikes to High of \$84.09 on Volume

Financial news for BMRN dated on 2016-11-03: Deutsche Bank Initiates Coverage On BioMarin Pharmaceutical Inc. - Common Stock at Buy

Financial news for BMRN dated on 2016-10-27: UPDATE: BioMarin Now Raises FY16 non-GAAP Loss Estimate From \$30M-\$50M To \$10M-\$30M

Financial news for BMRN dated on 2016-10-27: BioMarin Raises Guidance

Financial news for BMRN dated on 2016-10-27: BioMarin Reports Q3 GAAP Loss/Share of \$0.26 vs Est Loss/Share \$0.39, non-GAAP Income Of \$3M, Rev \$280M vs \$289.44M Est

Financial news for BMRN dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for BMRN dated on 2016-10-24: Solid Biosciences Granted US, EU Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy

Financial news for BMRN dated on 2016-10-19: UPDATE: Biomarin Vosoritide Data Shows Consistent Safety Profile At High Dose With ~50% Increase IN Mean Annualized Growth Velocity

Financial news for BMRN dated on 2016-10-19: BioMarin Presents Vosoritide Data

Financial news for BMRN dated on 2016-10-13: UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A, Requirement For Prophylactic Corticosteroids Removed

Financial news for BMRN dated on 2016-10-13: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMRN dated on 2016-10-11: Rich Ross Shares His Biotech Trades

Financial news for BMRN dated on 2016-10-10: Wedbush Boosts Target On Sarepta Shares From \$66 To \$72 Amid US Launch Of Exondys 51

Financial news for BMRN dated on 2016-09-22: 3 Reasons Sarepta Shares Rallied Following News Of \$225 Million Offering

Financial news for BMRN dated on 2016-09-21: Patent Trial And Appeal Board Hands Sarepta Another Big Win

Financial news for BMRN dated on 2016-09-21: BioMarin Announces Seeking Review of Ruling in Composition of Matter Patent Interference (No. 106,008)

Financial news for BMRN dated on 2016-09-20: After-Hours Decliners Sept. 20, 2016: MSTX Down 84%, MIRN 29%, BMRN 1%

Financial news for BMRN dated on 2016-09-20: Sarepta Shares Up ~1.4% in After-Hours Trade; BioMarin Shares Indicated Down ~2%

Financial news for BMRN dated on 2016-09-20: UPDATE: Sarepta Highlights Key Patent Protection for Eteplirsen, SRP-4053 Remains Valid

Financial news for BMRN dated on 2016-09-20: UPDATE: Sarepta Highlights Final Refusal of BioMarin's Interfering Claims Facilitates Commercialization of Eteplirsen in US

Financial news for BMRN dated on 2016-09-20: Sarepta Reports Favorable USPTO Decisions in Exon 51, Exon 53 Composition of Matter Patent Interference Cases Against BioMarin

Financial news for BMRN dated on 2016-09-20: Sarepta Shares Continue Rally As Analysts Flip To Positive

Financial news for BMRN dated on 2016-09-15: BioMarin Reports EMA Validation of Brineura MAA for Treatment of CLN2 Disease

Financial news for BMRN dated on 2016-09-14: SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen

Financial news for BMRN dated on 2016-09-06: Biomarin Reports Update On Brineura Program For CLN2 Disease FDA Designates This Submission As A Major Amendment To Application, Extending PDUFA Action Date By 3 Months To Apr. 27th, 2017

Financial news for BMRN dated on 2016-08-23: Watch These 7 Huge Call Purchases In Tuesday Trade

Financial news for BMRN dated on 2016-08-22: Option Alert: BMRN Oct16 110 Calls Sweep: 830 @ Above Ask! \$3.09: 1004 traded vs 401 OI: \$95.90 Ref

Financial news for BMRN dated on 2016-08-22: BioMarin Pharmaceutical +3.27% Premarket @\$95.00

Financial news for BMRN dated on 2016-08-22: 8 Stocks Moving In Monday's Pre-Market Session

Financial news for BMRN dated on 2016-08-09: There Have Been 20 Secondary Offerings Over The Last 2 Days

Financial news for BMRN dated on 2016-08-09: 20 Biggest Mid-Day Losers For Tuesday

Financial news for BMRN dated on 2016-08-09: BioMarin Prices Offering of 7.5M Shares at \$96/Share for Gross Proceeds \$720M

Financial news for BMRN dated on 2016-08-09: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BMRN dated on 2016-08-08: BioMarin Reports Public Offering of 7.5M Shares of Common Stock

Financial news for BMRN dated on 2016-08-04: Biomarin Sees FY16 Rev. \$1.1-\$1.15B vs. Est. \$1.09B

Financial news for BMRN dated on 2016-08-04: BioMarin Reports Q2 EPS \$(2.61) vs. Est. \$(0.52), Rev. \$300.1M vs. Est. \$278M

Financial news for BMRN dated on 2016-07-27: BioMarin Sets PDUFA Action Date as Jan. 27, '17

Financial news for BMRN dated on 2016-07-27: BioMarin Reports FDA Accepted BLA for Co.'s Cerliponase Alfa for CLN2 Disease

Financial news for BMRN dated on 2016-07-27: UPDATE: BioMarin Says 'Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval Filing'

Financial news for BMRN dated on 2016-07-27: UPDATE: BioMarin Results Demonstrate '6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10%'

Financial news for BMRN dated on 2016-07-27: BioMarin Reports PoC Data for BMN 270 Therapy in Hemophilia A: No Clinically Relevant Sustained Rises in ALT

Financial news for BMRN dated on 2016-07-21: BioMarin Reports Will Provide Updated Data for BMN 270 in Hemophilia A at XXXII Int'l Congress of World Federation of Meophilia, Will Hold Call to Discuss on Wed., Jul. 27

Financial news for BMRN dated on 2016-07-14: Option Alert: BMRN Jul16 95.0 Calls Sweep: 509 @ ASK \$0.40: 511 traded vs 2717 OI: Earnings 8/1 \$89.14 Ref

Financial news for BMRN dated on 2016-07-08: Option Alert: BMRN Aug16 100 Calls: 650 @ ASK \$5.50: 668 traded vs 2068 OI: Earnings 8/1 \$90.00 Ref

Financial news for BMRN dated on 2016-07-07: Medivation Bidders Will Have To Price In Talazoparib; BMO Sees \$68-\$76 Takeout Price

Financial news for BMRN dated on 2016-07-07: 11 Biggest Mid-Day Gainers For Thursday

Financial news for BMRN dated on 2016-07-07: Technical Alert: Bimoarin Pops And Drops After Renewed Interest From Roche

Financial news for BMRN dated on 2016-07-07: Benzinga's Volume Movers

Financial news for BMRN dated on 2016-07-07: Adam Feuerstein @adamfeuerstein Tweet: @TerryMSmith @Sport234a \$BMRN does get royalty on tala sales, so if that \$30B mkt opportunity promised by \$MDVN comes true... \$\$\$

Financial news for BMRN dated on 2016-07-07: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMRN dated on 2016-07-06: Roche said to have Renewed Interest in BioMarin -Betaville

Financial news for BMRN dated on 2016-06-27: Betaville's Ben Harrington Says Sanofi Could bid for Biomarin if Medivation Bid Fails

Financial news for BMRN dated on 2016-06-20: BioMarin Reports Acceptance of Late-Breaking Abstract for BMN 270 at WFH World Congress

Financial news for BMRN dated on 2016-06-17: Wedbush Analyst Says Sanofi Could Not Feasibly Drop Its Bid For Medivation To Shift Sight To Biomarin

Financial news for BMRN dated on 2016-06-17: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for BMRN dated on 2016-06-17: BiomMarin +3.9% Premarket @\$84.00

Financial news for BMRN dated on 2016-06-16: BioMarin IR Says Suspension of Recruitment in BMN 270 Trial Was Announced on April 20th at R&D Day; One Patient had Elevated Liver Enzymes

Financial news for BMRN dated on 2016-06-16: Adam Feuerstein @adamfeuerstein \$BMRN -- StreetAccount notes company previously disclosed temporary enrollment suspension in '270 hemophilia study.

Financial news for BMRN dated on 2016-06-16: Biomarin Shares Selling Off; Traders Attributing to Report Co has Suspended Recruitment in BMN 270 Trial

Financial news for BMRN dated on 2016-06-16: BioMarin Pharmaceutical Gene Therapy Study in Severe Haemophilia A Patients Suspended Participant Recruitment

Financial news for BMRN dated on 2016-06-16: BioMarin Shares Fall ~\$3.50 Over Last Few Mins

Financial news for BMRN dated on 2016-06-13: 6 Largest Price Target Changes For Monday

Financial news for BMRN dated on 2016-06-13: Credit Suisse Cuts BioMarin Price Target As Company Gives Up Revenue For Profit

Financial news for BMRN dated on 2016-06-03: There's Hope For BioMarin Beyond Kyndrisa

Financial news for BMRN dated on 2016-06-02: Biomarin Shares +5% @\$91.84; Traders Attributing to Negative News for Sarepta on Final Individual Patient Expanded Access Form Being Considered Positive for Biomarin

Financial news for BMRN dated on 2016-06-01: Goldman Sachs Still Bullish On BioMarin Pipeline Despite Kyndrisa Pullout

Financial news for BMRN dated on 2016-05-31: BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe

Financial news for BMRN dated on 2016-05-03: BioMarin Reports EMA Grants Accelerated Assessment for Cerliponase Alfa, Co. Seeks Priority Review In U.S.

Financial news for BMRN dated on 2016-04-28: BioMarin Sees FY16 Rev. \$1.05-\$1.1B vs. Est. \$1.09B

Financial news for BMRN dated on 2016-04-28: BioMarin Reports Q1 EPS \$(0.53) vs. Est. \$(0.79), Rev. \$236.7M vs. Est. \$240.45M

Financial news for BMRN dated on 2016-04-28: Short Sellers Dump Vertex, Load Up On Baxalta

Financial news for BMRN dated on 2016-04-22: Biomarin Shares Spiking, DealReporter Says Co May Be Attractive To Sanofi

Financial news for BMRN dated on 2016-04-21: BioMarin Says BMN 250 has been Granted Orphan Drug Designation by EC

Financial news for BMRN dated on 2016-04-21: BioMarin Reports Enrollment of First Patient in Phase 1/2 Trial of BMN 250 for Treatment of MPS IIIB

Financial news for BMRN dated on 2016-04-20: BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide

Financial news for BMRN dated on 2016-04-20: BioMarin Provides Program Update on Vosoritide in Achondroplasia

Financial news for BMRN dated on 2016-04-20: BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program, 2 High Dose Patients Showing Increasing Levels Of Factor VII Above 50%

Financial news for BMRN dated on 2016-04-19: Adam Feuerstein @adamfeuerstein Tweet: \$BMRN R&D event tomorrow. First airing of human data from its hemophilia A gene therapy program.

Financial news for BMRN dated on 2016-04-12: Chardan Analyst: Amicus Therapeutics Could Be Bought For \$22.50/Share

Financial news for BMRN dated on 2016-04-07: BMO Capital Initiates Coverage on Biomarin Pharmaceutical at Outperform

Financial news for BMRN dated on 2016-03-24: BioMarin Receives European Orphan Drug Designation for BMN 270, Currently Conducting Phase 1/2 Study To Evaluate Safety, Efficacy Of BMN 270 In Hemophilia A

Financial news for BMRN dated on 2016-03-22: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to \$109.00

Financial news for BMRN dated on 2016-03-21: BioMarin Announces Phase 3 Pegvaliase Study Meets Primary Endpoint

Financial news for BMRN dated on 2016-03-21: BioMarin Announces Phase 3 Study of Pegvaliase for Phenylketonuria Meets Primary Endpoint of Blood Phenylalanine Reduction ($p < 0.0001$)

Financial news for BMRN dated on 2016-03-11: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for BMRN dated on 2016-03-08: Baird Buying Ultragenyx And BioMarin

Financial news for BMRN dated on 2016-03-07: Baird Upgrades Biomarin Pharmaceutical to Outperform, Raises PT to \$110.00

Financial news for BMRN dated on 2016-03-07: Goldman Sachs Upgrades Biomarin Pharmaceutical to Conviction Buy

Financial news for BMRN dated on 2016-03-04: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for BMRN dated on 2016-03-03: Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises PT to \$114.00

Financial news for BMRN dated on 2016-03-01: BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A

Financial news for BMRN dated on 2016-03-01: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for BMRN dated on 2016-03-01: Earlier 8-K from BioMarin Showed Interim Conclusion from Phase 1/2 Study of BMN 190 in Children with CLN2 Disease 'Well-Tolerated' and 'Slows Progression of Functional Decline in Children

Financial news for BMRN dated on 2016-02-29: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for BMRN dated on 2016-02-29: BioMarin Rebrands RareConnections, Consolidating Co.'s Comprehensive Support, Services for Eligible Rare Disease Patients

Financial news for BMRN dated on 2016-02-26: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for BMRN dated on 2016-02-26: RBC Capital Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to \$125.00

Financial news for BMRN dated on 2016-02-26: Barclays Maintains Overweight on Biomarin Pharmaceutical, Lowers PT to \$105.00

Financial news for BMRN dated on 2016-02-25: Biomarin Sees FY16 Rev. \$1.05-\$1.1B vs. Est. \$1.15B

Financial news for BMRN dated on 2016-02-25: BioMarin Reports Q4 EPS \$0.39 vs. Est. \$0.99, Rev. \$227.9M vs. Est. \$224.38M

Financial news for BMRN dated on 2016-02-23: Leerink Swann Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to \$120.00

Financial news for BMRN dated on 2016-02-23: Oppenheimer Maintains Perform on Biomarin Pharmaceutical, Lowers PT to \$99.00

Financial news for BMRN dated on 2016-02-16: BioMarin's Carnage Could Be Buying Opportunity, Says Stifel

Financial news for BMRN dated on 2016-02-16: Stifel Nicolaus Upgrades Biomarin Pharmaceutical to Buy

Financial news for BMRN dated on 2016-02-08: Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

Financial news for BMRN dated on 2016-01-21: The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug

Financial news for BMRN dated on 2016-01-20: Why BioMarin's Pipeline Could Be Worth \$4 Billion-Plus

Financial news for BMRN dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for BMRN dated on 2016-01-20: Credit Suisse Initiates BMRN At Outperform, Focus Is Primarily On The Pipeline Potentially Worth Unadjusted ~\$4.1B, Says Re-Acquiring Rights For PKU Franchise 'was the right strategic move'

Financial news for BMRN dated on 2016-01-19: Credit Suisse Initiates Coverage on Biomarin Pharmaceutical at Outperform, Announces \$110.00 PT

Financial news for BMRN dated on 2016-01-14: UPDATE: BioMarin Highlights Kyndrisa MAA Remains Under Regulatory Review in Europe

Financial news for BMRN dated on 2016-01-14: BioMarin Reports FDA Issued CRL Related to Kyndrisa for DMD Amendable to Exon 51 Skipping

Financial news for BMRN dated on 2016-01-11: Adam Feuerstein Tweets: \$BMRN says 2016 revenue will exceed \$1B with or without drisapersen. Current consensus \$1.2B #JPM16

Financial news for BMRN dated on 2016-01-11: BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial

Financial news for BMRN dated on 2015-12-28: 8-K Filing Shows BioMarin Pharma Amended Kuvan Agreement With Ares Trading

Financial news for BMRN dated on 2015-12-18: BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa(tm) (drisapersen) New Drug Application by the PDUFA Date

Financial news for BMRN dated on 2015-12-08: Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

Financial news for BMRN dated on 2015-12-07: Wedbush's Moussatos Offers Probabilities for Upcoming Catalysts in Emerging Pharma Sector Heading Into '16: Discusses 14 Cos., Including BioMarin, Intercept, Regulus, Relypsa, Vitae, Xoma

Financial news for BMRN dated on 2015-11-25: BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish?

Financial news for BMRN dated on 2015-11-25: Biomarin Resumes Trade At \$90/Share, Spiking Higher

Financial news for BMRN dated on 2015-11-25: BioMarin Pharmaceutical to Resume Trading at 7:10 AM ET

Financial news for BMRN dated on 2015-11-24: FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-11-24: Volume Spike in Sarepta on Report of FDA Panel Vote on BioMarin DMD Treatment

Financial news for BMRN dated on 2015-11-24: UPDATE: 7 of 17 FDA Panel Members Vote That Strength Of Efficacy Evidence Of Drisapersen In Study 1 Has No Effect On The Persuasiveness Of The Study

Financial news for BMRN dated on 2015-11-24: 9 of 17 FDA Panel Members Vote That Strength Of Efficacy Evidence Of BioMarin's Drisapersen In Study 1 Weakens The Persuasiveness Of The Study

Financial news for BMRN dated on 2015-11-24: BioMarin Posts Presentation at FDA Advisory Committee Meeting

Financial news for BMRN dated on 2015-11-24: UPDATE: BioMarin Releases PR Confirming Stock Is Halted, FDA Meeting To Review NDA For Kyndrisa For Duchenne Muscular Dystrophy

Financial news for BMRN dated on 2015-11-24: BioMarine Pharma Halted, T-1 News Pending

Financial news for BMRN dated on 2015-11-23: Oppenheimer On Upcoming BioMarin Panel: Efficacy Concerns Circulate

Financial news for BMRN dated on 2015-11-23: NICE Recommends BioMarin's Vimizim for the Treatment of Morquio A Syndrome in England

Financial news for BMRN dated on 2015-11-22: Barron's Recap: 16 All-Star Women Financial Advisors

Financial news for BMRN dated on 2015-11-20: Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

Financial news for BMRN dated on 2015-11-20: Morning Market Losers

Financial news for BMRN dated on 2015-11-20: Sarepta Moving In Contrast To Biomarin In Pre-Market After Competing Drug Biomarin's Kyndrisa Data Analysis And Briefing Documents Released, Up From ~\$26/Share To \$32.71/Share

Financial news for BMRN dated on 2015-11-20: Biomarin Falls From \$103.13/Share To Low Of \$88.50/Share On FDA Briefing Documents And Analysis Of Kyndrisa, Now Trading Up To \$95/Share

Financial news for BMRN dated on 2015-11-20: Benzinga's Top #PreMarket Losers

Financial news for BMRN dated on 2015-11-20: Release Confirms BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa in Comparable Patients Across Three Randomized Studies

Financial news for BMRN dated on 2015-11-20: Biomarin Release Confirms FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping

Financial news for BMRN dated on 2015-11-20: Shares of BioMarin Indicated Down ~11%+ Following FDA Staff Review Related to Co.'s Drisapersen

Financial news for BMRN dated on 2015-11-18: Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Financial news for BMRN dated on 2015-11-18: Benzinga's Top Initiations

Financial news for BMRN dated on 2015-11-18: Oppenheimer Initiates Coverage on Biomarin Pharmaceutical at Perform, Announces \$119.00 PT

Financial news for BMRN dated on 2015-11-18: Goldman Sachs Initiates Coverage on Biomarin Pharmaceutical at Buy, Announces \$158.00 PT

Financial news for BMRN dated on 2015-11-17: Oppenheimer Initiates Coverage on Biomarin Pharmaceutical at Perform, Announces \$119.00 PT

Financial news for BMRN dated on 2015-11-13: Positive FDA Panel Vote Could Be Coming For BioMarin Pharma, Research Says

Financial news for BMRN dated on 2015-10-29: BioMarin Reports Q3 GAAP Loss of \$0.60/Share vs Loss of \$0.65/Share Est.

Financial news for BMRN dated on 2015-10-27: Biotech ETFs: Buy, Buy, Buy?

Financial news for BMRN dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for BMRN dated on 2015-10-15: BioMarin Reports FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-10-12: BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting

Financial news for BMRN dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for BMRN dated on 2015-10-01: BioMarin to Acquire Rights to Phenylketonuria Franchise From Merck Serono for Upfront Payment of EUR340M, Plus

Milestones

Financial news for BMRN dated on 2015-09-30: Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical And More

Financial news for BMRN dated on 2015-09-30: BioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International Congress of the World Muscle Society

Financial news for BMRN dated on 2015-09-30: Benzinga's Top #PreMarket Losers

Financial news for BMRN dated on 2015-09-30: Sarepta Reports US PTO Decision in Patent Interference Case with BioMarin

Financial news for BMRN dated on 2015-09-28: BioMarin Enrolls Initial Patient in Phase 1/2 Trial of Gene Therapy Drug Candidate BMN 270 for the Treatment of Hemophilia A

Financial news for BMRN dated on 2015-09-18: BioMarin Reports Kuvan Patent Challenge Settlement

Financial news for BMRN dated on 2015-09-16: What It's Like To Have Dinner With BioMarin Executives

Financial news for BMRN dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for BMRN dated on 2015-09-08: UBS: Biotech Will Continue To Outperform In 2015

Financial news for BMRN dated on 2015-08-31: BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting

Financial news for BMRN dated on 2015-08-25: Option Alert: \$BMRN Jan \$140 Call; 1232 Contracts @Ask @\$11.70; Now \$122.14

Financial news for BMRN dated on 2015-08-24: Benzinga's M&A Chatter for Monday August 24, 2015

Financial news for BMRN dated on 2015-08-24: Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing

Financial news for BMRN dated on 2015-08-24: Medivation Announces Acquisition of Worldwide Rights to Talazoparib from BioMarin, Will Pay \$410M Upfront

Financial news for BMRN dated on 2015-08-24: Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

Financial news for BMRN dated on 2015-08-21: In new note to subscribers, CMT Christian Sharp making bet that 15-20% correction is coming

Financial news for BMRN dated on 2015-08-21: UBS Analysts Might've Found Another BioMarin Catalyst

Financial news for BMRN dated on 2015-08-19: Treating Female Sexual Dysfunction (And How To Invest In It)

Financial news for BMRN dated on 2015-08-19: BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy

Financial news for BMRN dated on 2015-08-04: Why Two Wall Street Titans Love BioMarin Pharma

Financial news for BMRN dated on 2015-08-03: Biomarin Q2 Loss \$0.51 vs Loss \$0.53, Sales \$250.5M

Financial news for BMRN dated on 2015-07-27: With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI

Financial news for BMRN dated on 2015-07-27: Evercore ISI says Allergan may now engage in "large M&A," buy-side survey indicates Biogen, AbbVie, BioMarin, or a combination with Pfizer as possible takeout targets.

Financial news for BMRN dated on 2015-07-20: UPDATE: BioMarin Says ABRAZO Phase 2 Trial Met Protocol-Specified Threshold

Financial news for BMRN dated on 2015-07-20: BioMarin Gives Program Update for Talazoparib in Metastatic Breast Cancer

Financial news for BMRN dated on 2015-07-13: Short Sellers Shy Away From Biotech Stocks

Financial news for BMRN dated on 2015-06-29: BioMarin Reports FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-06-25: BioMarin Announced EMA Validates MAA For Drisapersen For Treatment Of Duchenne Muscular Dystrophy Amendable To Exon 51 Skipping

Financial news for BMRN dated on 2015-06-19: Baird Downgrades BioMarin Pharmaceutical To Neutral

Financial news for BMRN dated on 2015-06-19: Benzinga's Volume Movers

Financial news for BMRN dated on 2015-06-19: Benzinga's Top Downgrades

Financial news for BMRN dated on 2015-06-19: Baird Downgrades BioMarin Pharmaceutical to Neutral

Financial news for BMRN dated on 2015-06-18: Daily Movers: Welcoming Fitbit; BioMarin Soars Again, While Oracle Slumps

Financial news for BMRN dated on 2015-06-18: Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall

Financial news for BMRN dated on 2015-06-18: Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge

Financial news for BMRN dated on 2015-06-18: BioMarin's Results Are In: What Do They Mean?

Financial news for BMRN dated on 2015-06-18: Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views

Financial news for BMRN dated on 2015-06-18: Benzinga's Volume Movers

Financial news for BMRN dated on 2015-06-18: Morning Market Gainers

Financial news for BMRN dated on 2015-06-18: UPDATE: BioMarin Shares Rise 9% Premarket Following Announcement of Positive BMN 111 Data

Financial news for BMRN dated on 2015-06-18: Benzinga's Top #PreMarket Gainers

Financial news for BMRN dated on 2015-06-17: Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers

Financial news for BMRN dated on 2015-06-17: BioMarin Shares Rise 9.5% After-Hours Following Announcement of Positive BMN 111 Data

Financial news for BMRN dated on 2015-06-17: BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

Financial news for BMRN dated on 2015-06-17: SunTrust's 5 Biotech Picks For The Next 6 Months

Financial news for BMRN dated on 2015-06-15: Is BioMarin A Buy Ahead Of This Important Data Release?

Financial news for BMRN dated on 2015-06-09: Adam Feuerstein tweets "FDA DMD guidance is + for \$BMRN (if you are a \$BMRN supporter) FDA DMD guidance is + for \$SRPT (if you are a \$SRPT supporter.)"

Financial news for BMRN dated on 2015-06-08: BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-06-08: BioMarin Gives Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-06-05: Benzinga's Top Initiations

Financial news for BMRN dated on 2015-06-05: Barclays Initiates BioMarin Pharmaceutical With Overweight

Financial news for BMRN dated on 2015-06-05: Barclays: BioMarin Is A Buy, Sees

\$150/Share

Financial news for BMRN dated on 2015-06-05: Barclays Initiates Coverage on BiMarin Pharmaceutical at Overweight, Announces \$150.00 PT

Financial news for BMRN dated on 2015-05-22: CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacyclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy

Financial news for BMRN dated on 2015-05-20: The Street Sweeper Tweets: "\$SRPT up on FDA plan. Long way to go.Canaccord says if \$BMRN's drug is approved 1st, pressure to approve SRPT "may decrease." We're short."

Financial news for BMRN dated on 2015-05-01: Is BioMarin Still An Outperform At This Research Firm?

Financial news for BMRN dated on 2015-04-30: BioMarin Pharma Reports Q1 Adj EPS -\$0.16, GAAP EPS -\$0.43 Vs Est -\$0.53, Sales \$203.3M Vs Est \$202.82M, Sees 2015 Revs \$850M-\$880

Financial news for BMRN dated on 2015-04-27: BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial news for BMRN dated on 2015-04-23: BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting

Financial news for BMRN dated on 2015-04-23: Wedbush: BioMarin Pharma Still Worth \$104/Share

Financial news for BMRN dated on 2015-04-21: BioMarin Pharmaceutical Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for BMRN dated on 2015-04-06: 16 Biotech Catalysts SunTrust Is Tracking

Financial news for BMRN dated on 2015-04-01: QuickLogic, Sonic Corp, BioMarin Pharmaceutical Lead Wednesday's After-Hours Movers

Financial news for BMRN dated on 2015-03-31: Hearing Deal Reporter Saying BioMarin Not in Active Takeover Talks

Financial news for BMRN dated on 2015-03-30: BioMarin Tells Benzinga They Will be Attending DB Conference on May 5 in Boston, They Have Not Cancelled Any Conferences

Financial news for BMRN dated on 2015-03-30: Hearing BioMarin has Cancelled Out of Upcoming Conferences

Financial news for BMRN dated on 2015-03-30: BioMarin Reports One Oral, Seven Poster Presentations at ACMGG Annual Meeting

Financial news for BMRN dated on 2015-03-27: Why BioMarin Pharmaceutical Is Surging

Financial news for BMRN dated on 2015-03-27: Benzinga's Volume Movers

Financial news for BMRN dated on 2015-03-27: Stocks Hitting 52-Week Highs

Financial news for BMRN dated on 2015-03-27: Morning Market Gainers

Financial news for BMRN dated on 2015-03-27: UPDATE: Deutsche Bank Analyst on BioMarin Sees 'Potential M&A Take Out in One Year ~\$194-\$271/Share'

Financial news for BMRN dated on 2015-03-27: Benzinga's Top #PreMarket Gainers

Financial news for BMRN dated on 2015-03-27: UPDATE: BioMarin Shares Rise 8% Premarket on Rumor of Shire Interest, Deutsche Bank Raising PT to \$140 from \$90

Financial news for BMRN dated on 2015-03-27: BioMarin Shares Rise ~7% on Blog Report Indicating Potential Bid from Shire

Financial news for BMRN dated on 2015-03-26: Is It Closing Time At The Biotech Bar?

Financial news for BMRN dated on 2015-03-23: What's Causing The Rally In BioMarin? CEO Answers

Financial news for BMRN dated on 2015-03-17: Myriad, BioMarin Expand Collaboration to Evaluate myChoice HRD as a Companion Diagnostic for Talazoparib

Financial news for BMRN dated on 2015-03-13: Short Sellers Still Attracted To Biotech

Stocks

Financial news for BMRN dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for BMRN dated on 2015-03-05: Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

Financial news for BMRN dated on 2015-02-25: What Evercore Is Watching At BioMarin Pharmaceutical

Financial news for BMRN dated on 2015-02-25: BioMarin Reports Q4 Loss of \$0.47/Share vs Loss of \$0.58/Share Est., Sales \$230.9M vs \$190M Est.

Financial news for BMRN dated on 2015-02-23: Benzinga's M&A Chatter for Monday February 23, 2015

Financial news for BMRN dated on 2015-02-23: Update: Biomarin, Shire Potential Buyers for PTC Therapeutics, According to Sources -Reuters

Financial news for BMRN dated on 2015-02-23: Adam Feuerstein @adamfeuerstein Tweet: \$BMRN is interested in buying \$PTCT? That's hard to believe.

Financial news for BMRN dated on 2015-02-20: BioMarin To Report Revenue In-line With Consensus, Wedbush Says

Financial news for BMRN dated on 2015-02-17: Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

Financial news for BMRN dated on 2015-01-30: BioMarin Reports Final Results of Tender Offer for Prosensa's Shares, Closing of Subsequent Offering Period

Financial news for BMRN dated on 2015-01-22: BioMarin Prices 8.5M Share Offering @\$93.25/Share

Financial news for BMRN dated on 2015-01-21: BioMarin Announces 7.25M Share Public Offering of Common Stock

Financial news for BMRN dated on 2015-01-21: State Of The Union Lights Up Biotech

Financial news for BMRN dated on 2015-01-16: Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

Financial news for BMRN dated on 2015-01-15: BioMarin Reports Closing of Tender Offer for Prosensa's Shares

Financial news for BMRN dated on 2015-01-14: UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data

Financial news for BMRN dated on 2015-01-12: UPDATE: BioMarin Pharmaceutical Reports in All 9 of Patients Followed for 6-15 Months, Treatment Appears to Show Stabilization of Disease

Financial news for BMRN dated on 2015-01-12: BioMarin Provides Positive Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190

Financial news for BMRN dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for BMRN dated on 2015-01-06: What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

Financial news for BMRN dated on 2014-12-29: Monday Social Sentiment Roundup: PNC Financial, Manitowoc, BioMarin Pharmaceutical Are All Moving

Financial news for BMRN dated on 2014-12-29: BioMarin Reports Approval of VIMIZIM in Japan

Financial news for BMRN dated on 2014-12-11: UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

Financial news for BMRN dated on 2014-12-10: FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

Financial news for BMRN dated on 2014-12-10: BioMarin Reports FDA Granted Orphan Drug Designation for NAGLU Fusion Protein, BMN, 250, for Treatment of MPS IIIB

Financial news for BMRN dated on 2014-12-09: BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

Financial news for BMRN dated on 2014-12-07: BioMarin's VIMIZIM Approved by Australian Therapeutic Goods Administration for Treatment of Morquio A Syndrome

Financial news for BMRN dated on 2014-12-03: BioMarin Shares Volatile Following Appearance by CEO Bienaime on CNBC's Fast Money, Discussed Prospects for Prosensa Deal, Drug Approval

Financial news for BMRN dated on 2014-11-26: BioMarin's MPS IIIB Treatment Receives FDA Orphan Drug Designation

Financial news for BMRN dated on 2014-11-24: Benzinga's M&A Chatter for Monday November 24, 2014

Financial news for BMRN dated on 2014-11-24: Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetrphase Pharmaceuticals Shares Spike Higher

Financial news for BMRN dated on 2014-11-24: Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

Financial news for BMRN dated on 2014-11-24: Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For \$17.75/Share

Financial news for BMRN dated on 2014-11-24: Benzinga's Volume Movers

Financial news for BMRN dated on 2014-11-24: Stocks Hitting 52-Week Highs

Financial news for BMRN dated on 2014-11-24: Morning Market Movers

Financial news for BMRN dated on 2014-11-24: BioMarin Pharmaceuticals To Acquire Prosensa

Financial news for BMRN dated on 2014-11-24: Benzinga's Top #PreMarket Gainers

Financial news for BMRN dated on 2014-11-24: US Stock Futures Up Ahead Of Economic Data

Financial news for BMRN dated on 2014-11-24: Prosensa Holding Shares Rise 61% Premarket on BioMarin Acquisition Announcement; Sarepta Shares Up 11%

Financial news for BMRN dated on 2014-11-24: BioMarin to Acquire Prosensa for \$17.75/Share

Financial news for BMRN dated on 2014-11-24: BioMarin to Pay Up to \$840M for Prosensa

Financial news for BMRN dated on 2014-11-10: Stocks Hitting 52-Week Highs

Financial news for BMRN dated on 2014-11-10: Benzinga's Top Upgrades

Financial news for BMRN dated on 2014-11-10: Goldman Sachs Upgrades BioMarin Pharmaceutical To Buy

Financial news for BMRN dated on 2014-11-10: Goldman Sachs Upgrades BioMarin Pharmaceutical Inc. to Buy, Raises PT to \$104.00

Financial news for BMRN dated on 2014-10-27: Wedbush Maintains Neutral on BioMarin Pharmaceutical Inc., Raises PT to \$77.00

Financial news for BMRN dated on 2014-10-23: BioMarin Pharmaceutical Reported Q3 Adj. Net Loss \$0.16 Per Share

Financial news for BMRN dated on 2014-10-23: BioMarin Pharmaceutical Inc. Reports Q3 EPS of \$0.50 vs \$(0.22) Est

Financial news for BMRN dated on 2014-10-21: Benzinga's M&A Chatter for Tuesday October 21, 2014

Financial news for BMRN dated on 2014-10-21: Biomarin Pharmaceutical Shares Rise 3% as Adam F Mentions it as Possible Shire Target

Financial news for BMRN dated on 2014-09-24: BioMarin Reports FDA Has Received Paragraph IV Notice Letter for Kuvan(R)

Financial news for BMRN dated on 2014-08-26: From BioMarin 8-K: Lowers FY2014 Sales Guidance from \$745.0M-765.0M to \$680.0M-700.0M vs \$768.70M Est

Financial news for BMRN dated on 2014-08-06: BioMarin Weathers The Storm

Financial news for BMRN dated on 2014-07-31: Biomarin Pharma Shares Spike to High on

Volume

Financial news for BMRN dated on 2014-07-30: BioMarin Pharmaceutical Inc. Reports Q2 EPS of \$(0.23) Which May Not Compare \$(0.41) Est; Revenue of \$191.80M Which May Not Compare \$159.69M Est

Financial news for BMRN dated on 2014-07-07: BioMarin Announces Health Canada Approval of VIMIZIM for Treatment of Morquio A Syndrome

Financial news for BMRN dated on 2014-06-11: UBS Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces \$74.00 PT

Financial news for BMRN dated on 2014-06-09: UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

Financial news for BMRN dated on 2014-06-09: Benzinga's Top Upgrades

Financial news for BMRN dated on 2014-06-09: Credit Suisse Upgrades BioMarin Pharmaceutical Inc. to Outperform, Maintains \$73.00 PT

Financial news for BMRN dated on 2014-06-09: Credit Suisse Upgrades BioMarin Pharmaceutical Inc. to Outperform

Financial news for BMRN dated on 2014-06-03: Option Alert: Biomarin Pharmaceutical Jun \$70 Call; 2,620 Contract Trade at Ask @\$0.50; OI 449; Currently \$61.46

Financial news for BMRN dated on 2014-05-02: Nomura Maintains Neutral on BioMarin Pharmaceutical Inc., Lowers PT to \$77.00

Financial news for BMRN dated on 2014-05-01: BioMarin Pharmaceutical Inc. Reports Q1 EPS of \$(0.01) vs \$(0.46) Est; Revenue of \$151.60M vs \$145.51M Est

Financial news for BMRN dated on 2014-05-01: BioMarin Pharmaceutical Inc. Reports Q1 EPS of \$(0.27) vs \$(0.46) Est; Revenue of \$151.60M vs \$145.51M Est

Financial news for BMRN dated on 2014-04-28: BioMarin Shares Move Lower Despite Release Highlighting EC Approval/Orphan Drug Status for VIMIZIM for Treatment of Morquio A Syndrome

Financial news for BMRN dated on 2014-04-14: FDA Extends Market Exclusivity Six Months for BioMarin's KUVAN

Financial news for BMRN dated on 2014-03-25: Shares of BioMarin Down ~3.4% Over Last 10 Mins

Financial news for BMRN dated on 2014-03-25: UPDATE: News of BioMarin Appointment of Slamon as Director Was Issued in Press Release on Mar 21st

Financial news for BMRN dated on 2014-03-25: Form 8-K from BioMarin Shows Appointment of Dennis Slamon to Board

Financial news for BMRN dated on 2014-03-25: Goldman Sachs Downgrades BioMarin Pharmaceutical Inc. to Neutral, Maintains \$84.00 PT

Financial news for BMRN dated on 2014-03-12: BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for BMRN dated on 2014-03-05: BioMarin Prices 1.5M Share Offering of Common Stock

Financial news for BMRN dated on 2014-03-04: BioMarin Announces Offering of 1.5M Shares of Common Stock

Financial news for BMRN dated on 2014-03-04: Biotechs vs. Pharmaceuticals: What's the Difference?

Financial news for BMRN dated on 2014-02-27: Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

Financial news for BMRN dated on 2014-02-27: Nomura Maintains Neutral on BioMarin Pharmaceutical Inc., Raises PT to \$86.00

Financial news for BMRN dated on 2014-02-26: BioMarin Pharmaceutical Inc. Reports Q4 EPS of \$(0.44) vs \$(0.35) Est; Revenue of \$146.90M vs \$146.07M Est

Financial news for BMRN dated on 2014-02-21: EMA Isuses New Compassionate-Use Programme

Financial news for BMRN dated on 2014-02-20: BioMarin Receives Position Opinion from

CHMP for Vimizim

Financial news for BMRN dated on 2014-02-18: Top Trending Tickers On StockTwits For February 18

Financial news for BMRN dated on 2014-02-18: BioMarin Pharmaceutical Inc. Sees FY2014 Sales \$650.0M-680.0M, Sees Non-GAAP Loss in \$100M-130M Range

Financial news for BMRN dated on 2014-02-14: BioMarin Confirms FDA Approval for VIMIZIM

Financial news for BMRN dated on 2014-02-14: FDA Approves Vimizim to Treat Rare Congenital Enzyme Disorder

Financial news for BMRN dated on 2014-02-13: BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

Financial news for BMRN dated on 2014-02-11: BioMarin Announces Selection of NAGLU Fusion Protein Drug Development

Financial news for BMRN dated on 2014-01-29: New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

Financial news for BMRN dated on 2014-01-21: BioMarin Confirms Deal with Repligen for HDACI Portfolio, Will Pay \$2M Upfront

Financial news for BMRN dated on 2014-01-21: Repligen Announces Asset Buy Deal with BioMarin for HDACI Portfolio, Will Receive Upfront Payment of \$2M, Has Potential for Added Milestones of Up to \$160M

Financial news for BMRN dated on 2014-01-13: BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development, Sees Initiating Clinical Study with BMN 270 in Early 2015

Financial news for BMRN dated on 2014-01-11: Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)

Financial news for BMRN dated on 2014-01-08: Catalyst Pharma Says Study of Cardiac Safety in Phase 3 Trial of Firdapse Met Primary Endpoint

Financial news for BMRN dated on 2014-01-08: Nomura Initiates Coverage on BioMarin Pharmaceutical Inc. at Neutral, Announces \$75.00 PT

Financial news for BMRN dated on 2014-01-06: Catalyst Pharma Reports Successful Completion of Type B FDA Meeting, Will Submit Data from Added In-Vitro Preclinical Trial

Financial news for BMRN dated on 2013-12-23: Form 8-K from Biomarin Pharma Shows Pact to Buy San Rafael Corp. Center for \$116.5M, Deposited \$10M

Financial news for BMRN dated on 2013-12-05: Option Alert: Biomarin December \$70/Janaury \$75 Call Spread; 2,000 Spread Contract Trade; Currently \$70.00

Financial news for BMRN dated on 2013-12-04: BioMarin Submits VIMIZIM NDS to Health Canada for Treatment of Morquio A Syndrome Under Priority Review Status

Financial news for BMRN dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns

Financial news for BMRN dated on 2013-11-27: UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook

Financial news for BMRN dated on 2013-11-26: Piper Jaffray Reinstates Overweight on BioMarin Pharmaceutical Inc.

Financial news for BMRN dated on 2013-11-21: Option Alert: Biomarin December \$80 Call; 2,500 Contract Trade at Ask @\$0.65; Currently \$70.71

Financial news for BMRN dated on 2013-11-20: Benzinga's Top #PreMarket Gainers

Financial news for BMRN dated on 2013-11-20: Myriad Genetics Says Received Second HRD Pact with BioMarin

Financial news for BMRN dated on 2013-11-19: Shares of BioMarin Now Up 5+

Financial news for BMRN dated on 2013-11-19: BioMarin Shares Resume Trading, Now Up Just 0.66%

Financial news for BMRN dated on 2013-11-19: Shares of BioMarin to Resume Trading at

5:30PM EST

Financial news for BMRN dated on 2013-11-19: BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment of Patients with Morquio A Syndrome

Financial news for BMRN dated on 2013-11-19: FDA Panel Votes BioMarin's Vimizim Should Be Approved

Financial news for BMRN dated on 2013-11-19: FDA Panel Votes 16-5 BioMarin's NDA for Vimizim Does Not Raise Safety Concerns

Financial news for BMRN dated on 2013-11-19: FDA Advisory Committee Says BioMarin's Data Shows Vimizim Works for Rare Disease

Financial news for BMRN dated on 2013-11-19: BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic Drugs Advisory Committee

Financial news for BMRN dated on 2013-11-19: BioMarin Says Stock Halted Ahead of FDA Advisory Committee for Review of Vimizim Application

Financial news for BMRN dated on 2013-11-15: BioMarin Reports French ATU Granted for Vimizim for the Treatment of Morquio

Financial news for BMRN dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for BMRN dated on 2013-10-31: BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer

Financial news for BMRN dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacoclics (BIIB, BMRN, PCYC)

Financial news for BMRN dated on 2013-10-24: BioMarin Pharmaceutical Inc. Reports Q3 EPS of \$(0.38) vs \$(0.30) Est

Financial news for BMRN dated on 2013-10-24: US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients

Financial news for BMRN dated on 2013-10-20: BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC International Conference

Financial news for BMRN dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for BMRN dated on 2013-10-07: BioMarin Files Automatic Mixed Securities Shelf

Financial news for BMRN dated on 2013-09-29: BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ECC 2013

Financial news for BMRN dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for BMRN dated on 2013-09-23: BioMarin Reports First Patient in Phase 1/2 Trial for BMN 190 for Treatment of NCL Type 2

Financial news for BMRN dated on 2013-09-20: Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate

Financial news for BMRN dated on 2013-09-19: Benzinga's M&A Chatter for Thursday September 19, 2013

Financial news for BMRN dated on 2013-09-19: BioMarin Shares Hanging Onto Gains Despite Comment from Roche CEO Co. Not Raising Financing, Note from Wells Fargo Saying BioMarin Not a Clean Fit for Roche

Financial news for BMRN dated on 2013-09-19: Benzinga's Volume Movers

Financial news for BMRN dated on 2013-09-19: Biomarin Shares Pullback on Roche CEO Comments that Company is Not Raising Financing

Financial news for BMRN dated on 2013-09-19: Benzinga's Top Pre-Market Gainers

Financial news for BMRN dated on 2013-09-19: Roche Declines Comment on Rumored Bid for Biomarin Pharmaceutical

Financial news for BMRN dated on 2013-09-19: UPDATE: Biomarin Shares Rise 8% on Report Roche May Bid Up to \$105/Share

Financial news for BMRN dated on 2013-09-19: Hearing Deal Reporter Says Roche May Acquire Biomarin for \$95-\$105/Share

Financial news for BMRN dated on 2013-09-18: UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate Risk/Reward, Expected Slower Data Flow

Financial news for BMRN dated on 2013-09-18: Benzinga's Top Pre-Market Gainers

Financial news for BMRN dated on 2013-09-18: Jefferies Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to \$86.00

Financial news for BMRN dated on 2013-09-18: Stifel Nicolaus Downgrades BioMarin Pharmaceutical Inc. to Hold, Removes \$70.00 PT

Financial news for BMRN dated on 2013-09-17: Biomarin CEO Bienaim: 'Our New Drug Should Double Our Revenue in the Next Few Years'

Financial news for BMRN dated on 2013-09-17: Biomarin CEO Bienaim: 'Most of Our Drugs are for Ultra Orphan Disorders'

Financial news for BMRN dated on 2013-09-17: Biomarin Pharmaceutical Shares Move Higher Ahead of Jim Cramer Interview with CEO Jean-Jacques Bienaim

Financial news for BMRN dated on 2013-09-14: Alexion, Pharmacoclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for BMRN dated on 2013-09-05: Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to \$85.00

Financial news for BMRN dated on 2013-07-29: Stocks to Watch for July 29, 2013

Financial news for BMRN dated on 2013-07-25: Biomarin Pharma Expecting FY Net Loss \$160-185M vs Prior Guidance for Loss of \$170-195M

Financial news for BMRN dated on 2013-07-25: BioMarin Pharmaceutical Inc. Reports Q2 EPS of \$(0.16) vs \$(0.29) Est; Revenue of \$136.81M vs \$134.33M Est

Financial news for BMRN dated on 2013-07-25: BioMarin Provides BMN 673 Program Update

Financial news for BMRN dated on 2013-07-01: BioMarin Announces Marketing Application for Vimizim Submitted to Brazilian Regulators

Financial news for BMRN dated on 2013-06-05: A Peek Into The Market Before The Trading Starts

Financial news for BMRN dated on 2013-06-05: BioMarin Announces Initiation of Phase 3 PEG-PAL Trial for PKU

Financial news for BMRN dated on 2013-06-04: UPDATE: Deutsche Bank Upgrades BioMarin to Buy on Weak Stock Opportunity

Financial news for BMRN dated on 2013-06-03: BioMarin CEO Bienaim: 'AstraZeneca is a Significant Competitor, But we are 1000 Times more Potent than the Company'

Financial news for BMRN dated on 2013-06-03: BioMarin CEO Bienaim: 'Our Product is One Tablet/Day'

Financial news for BMRN dated on 2013-06-03: BioMarin CEO Bienaim: 'Ovarian Results were Pretty Astonishing, Breast Results were also Good'

Financial news for BMRN dated on 2013-06-03: Jim Cramer Interviews CEO Jean-Jacques Bienaim of BioMarin Pharmaceutical on Mad Money

Financial news for BMRN dated on 2013-06-03: Deutsche Bank Upgrades BioMarin Pharmaceutical Inc. to Buy, Maintains \$75.00 PT

Financial news for BMRN dated on 2013-06-03: UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results

Financial news for BMRN dated on 2013-06-03: Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News

Financial news for BMRN dated on 2013-06-03: Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings

Financial news for BMRN dated on 2013-06-03: BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, \$70 Target

Financial news for BMRN dated on 2013-06-03: Hearing Piper Defending Biomarin

Financial news for BMRN dated on 2013-06-03: BioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting

Financial news for BMRN dated on 2013-05-31: UPDATE: Credit Suisse Initiates BioMarin Pharmaceutical at Neutral on Revenue Growth Forecast

Financial news for BMRN dated on 2013-05-31: Credit Suisse Initiates Coverage on BioMarin Pharmaceutical Inc. at Neutral, Announces \$68.00 PT

Financial news for BMRN dated on 2013-05-30: Biomarin Announces FDA Acceptance of Vimizim BLA, Receives Priority Review Designation

Financial news for BMRN dated on 2013-05-30: Biomarin's Vimizim MAA Validated by the EMA

Financial news for BMRN dated on 2013-05-07: Goldman Sachs Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces \$80.00 PT

Financial news for BMRN dated on 2013-04-25: BioMarin Pharmaceutical Inc. Reports Q1 EPS of \$(0.31) vs \$(0.30) Est; Revenue of \$127.90M vs \$131.45M Est

Financial news for BMRN dated on 2013-04-01: BioMarin Submits CTA for BMN-190 for Batten Disease

Financial news for BMRN dated on 2013-03-25: Biomarin Closes Added Partial Exchange of Convertible Notes Due 2017

Financial news for BMRN dated on 2013-03-20: UPDATE: Jefferies Raises PT on BioMarin Pharmaceutical as BMN-701 Moves Forward

Financial news for BMRN dated on 2013-03-20: UPDATE: Wedbush Raises PT on BioMarin Pharmaceuticals on Positive Phase 2 Data

Financial news for BMRN dated on 2013-03-20: UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results

Financial news for BMRN dated on 2013-03-20: UPDATE: Deutsche Bank Raises PT on BioMarin Pharmaceuticals on Pipeline Outlook

Financial news for BMRN dated on 2013-03-20: Piper Jaffray Maintains Overweight on BioMarin Pharmaceutical Inc., Raises PT to \$70.00

Financial news for BMRN dated on 2013-03-20: Deutsche Bank Maintains Hold on BioMarin Pharmaceutical Inc., Raises PT to \$59.00

Financial news for BMRN dated on 2013-03-19: BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Trials, Sees Phase 2/3 Switching Trial by End of 2013

Financial news for BMRN dated on 2013-02-21: BioMarin Pharmaceutical Inc. Sees FY2013 Sales \$530.0M-555.0M vs \$555.70M Est

Financial news for BMRN dated on 2013-02-21: BioMarin Pharmaceutical Inc. Reports Q4 EPS of \$(0.43) vs \$(0.27) Est; Revenue of \$131.94M vs \$129.74M Est

Financial news for BMRN dated on 2013-02-19: Piper Jaffray Maintains Overweight on BioMarin Pharmaceutical Inc., Raises PT to \$64.00

Financial news for BMRN dated on 2013-02-19: BioMarin Reports Statistically Significant Changes in Kuvan Responding PKU Patients

Financial news for BMRN dated on 2013-02-19: Jefferies Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to \$65.00

Financial news for BMRN dated on 2013-02-12: UPDATE: Canaccord Genuity Raises PT to \$71 on BioMarin Pharmaceutical on Upcoming Catalysts

Financial news for BMRN dated on 2013-02-12: Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to \$71.00

Financial news for BMRN dated on 2013-02-01: UBS Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to \$67.00

Financial news for BMRN dated on 2013-01-25: Wunderlich Suspends Hold Rating on BioMarin Pharmaceutical Inc., Removes \$40.00 PT

Financial news for BMRN dated on 2013-01-22: UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Financial news for BMRN dated on 2013-01-22: Stifel Nicolaus Upgrades BioMarin Pharmaceutical Inc. to Buy, Announces \$67.00 PT

Financial news for BMRN dated on 2013-01-22: Stifel Nicolaus Upgrades BioMarin Pharmaceutical Inc. to Buy

Financial news for BMRN dated on 2013-01-08: Reuters Reporting BioMarin CEO Said Co. Won't Sell Itself, Even for 25-30% Premium

Financial news for BMRN dated on 2013-01-07: BioMarin Buys Zacharon Pharma for \$10M

Financial news for BMRN dated on 2013-01-02: Janney Capital Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces \$60.00 PT

Financial news for BMRN dated on 2013-01-02: J.P. Morgan Reiterates Overweight Rating, \$60 PT on BioMarin Pharmaceutical

Financial news for BMRN dated on 2012-12-07: UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral with \$46 PT

Financial news for BMRN dated on 2012-12-02: BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November

Financial news for BMRN dated on 2012-11-15: BioMarin Halted on Circuit Breaker

Financial news for BMRN dated on 2012-11-06: Barclays Maintains BioMarin Pharmaceuticals at Overweight, Raises PT from \$46 to \$54

Financial news for BMRN dated on 2012-11-06: Brean Murray Downgraded BioMarin Pharmaceuticals from Buy to Hold

Financial news for BMRN dated on 2012-11-05: Wedbush Securities Maintains BioMarin Pharmaceuticals at Neutral, Raises PT from \$41 to \$46

Financial news for BMRN dated on 2012-11-05: Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

Financial news for BMRN dated on 2012-11-05: UPDATE: Canaccord Genuity Raises PT to \$56 on BioMarin Pharmaceutical on Value Inflection Outlook

Financial news for BMRN dated on 2012-11-05: Citigroup Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$47 to \$61

Financial news for BMRN dated on 2012-11-05: Canaccord Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$52 to \$56

Financial news for BMRN dated on 2012-11-05: Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$46 to \$60

Financial news for BMRN dated on 2012-11-05: Mid Morning Market Update: Markets Decline, Stifel Financial Acquires KBW

Financial news for BMRN dated on 2012-11-05: Stocks Hitting 52-Week Highs

Financial news for BMRN dated on 2012-11-05: BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

Financial news for BMRN dated on 2012-10-25: BioMarin Pharmaceuticals Reports Q3 EPS \$-0.04 vs \$-0.20 Est; Revenues \$128.12M vs \$127.38M Est

Financial news for BMRN dated on 2012-10-03: UPDATE: Jefferies Raises PT to \$46 on BioMarin Pharmaceutical Ahead of GALNS Data

Financial news for BMRN dated on 2012-10-03: Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$44 to \$46

Financial news for BMRN dated on 2012-09-27: JP Morgan Maintains BioMarin Pharmaceuticals at Overweight, Raises PT from \$47 to \$50

Financial news for BMRN dated on 2012-09-27: Wedbush Securities Maintains BioMarin Pharmaceuticals at Neutral, Raises PT from \$37 to \$39

Financial news for BMRN dated on 2012-09-26: BioMarin Announces Decision to Start Phase 3 Program for PEG-PAL; Says Phase 2 Meeting with FDA in Q1, Drug Generally Well-Tolerated in Phase 2

Financial news for BMRN dated on 2012-09-12: William Blair on BioMarin Pharmaceuticals

Financial news for BMRN dated on 2012-09-07: Biomarin Speaking at Conference, Guides FY12 Revenue About \$500M vs \$496.36M Est

Financial news for BMRN dated on 2012-08-27: Deutsche Bank Downgrades BioMarin From Buy to Hold

Financial news for BMRN dated on 2012-08-27: Benzinga's Top Downgrades

Financial news for BMRN dated on 2012-08-27: UPDATE: Deutsche Bank Downgrades BioMarin Pharmaceuticals to Hold on GALNS Risk/Reward

Financial news for BMRN dated on 2012-08-27: Deutsche Bank Downgrades BioMarin Pharmaceuticals from Buy to Hold, Announces PT of \$45

Financial news for BMRN dated on 2012-08-24: Barclays Initiates Coverage on BioMarin Pharmaceuticals at Overweight, Announces PT of \$46

Financial news for BMRN dated on 2012-08-02: Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$40 to \$44

Financial news for BMRN dated on 2012-08-01: BioMarin Pharmaceuticals Reports Q2 EPS \$-0.27 vs \$-0.21 Est; Revenues \$124M vs \$121.69M Est

Financial news for BMRN dated on 2012-07-25: BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for BMRN dated on 2012-07-23: Morgan Stanley Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$43 to \$52

Financial news for BMRN dated on 2012-07-13: Option Alert: BioMarin Pharmaceutical August 55 Call; Block Trade: 2,500 Contracts @\$0.60, Currently \$43.47

Financial news for BMRN dated on 2012-07-11: Biomarin Pharmaceutical Spiking Lower

Financial news for BMRN dated on 2012-07-10: Option Alert: BioMarin Pharmaceutical August 45 Call; Block Trade: 10,076 Contracts @\$1.90, Currently \$42.17

Financial news for BMRN dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for BMRN dated on 2012-06-29: BioMarin Pharmaceutical Hits New 52-Week High on Continued Takeover Chatter

Financial news for BMRN dated on 2012-06-29: ThinkEquity Initiates Coverage on BioMarin Pharmaceuticals at Buy

Financial news for BMRN dated on 2012-06-28: Benzinga's M&A Chatter for Thursday June 28, 2012

Financial news for BMRN dated on 2012-06-28: Spokesperson for BioMarin Pharmaceutical Won't Comment on Guardian Report on Takeover Bids

Financial news for BMRN dated on 2012-06-28: Editor of Little Bear Blog is Long BioMarin Pharmaceutical on Takeover Chatter

Financial news for BMRN dated on 2012-06-28: UPDATE: BioMarin Spikes Higher on Report GlaxoSmithKline, Sanofi, Biogen Could Bid \$60/Share -Guardian

Financial news for BMRN dated on 2012-06-28: Biomarin Spikes Higher on Takeover Chatter

Financial news for BMRN dated on 2012-06-19: BioMarin CEO Bienaim: 'We Look at a Significant Improvement in a Small Patient Population'

Financial news for BMRN dated on 2012-06-19: BioMarin CEO Bienaim: 'All the Patients We Serve Are Extremely Sick With Life Threatening Diseases'

Financial news for BMRN dated on 2012-06-19: Jim Cramer Interviews CEO Jean-Jacques Bienaim of BioMarin Pharmaceutical on Mad Money

Financial news for BMRN dated on 2012-06-19: Benzinga's M&A Chatter for Tuesday June 19, 2012

Financial news for BMRN dated on 2012-06-19: BioMarin Pharmaceutical Spokesperson Won't Comment on dealReporter Story Regarding Prospects of Sale of the Company

Financial news for BMRN dated on 2012-06-19: Hearing Negative dealReporter Article on Biomarin Pharmaceutical

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Reiterates 2012 Revenue Outlook \$475M to \$510M, vs Consensus \$494.9M

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Says Have Sales in 45 Countries

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Says Revenue Stream is Growing

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Says Revenues over Next 2 Years Going into R&D

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Commenting on Batten Disease Study

Financial news for BMRN dated on 2012-06-14: BioMarin Pharmaceutical Presents at William Blair Growth Stock Conference

Financial news for BMRN dated on 2012-06-12: Benzinga's M&A Chatter for Tuesday June 12, 2012

Financial news for BMRN dated on 2012-06-12: Spokesperson for BioMarin Pharmaceutical Won't Comment on Earlier Takeover Chatter

Financial news for BMRN dated on 2012-06-12: Benzinga's Top Pre-Market Gainers

Financial news for BMRN dated on 2012-06-08: From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, FV To \$35

Financial news for BMRN dated on 2012-06-01: Benzinga's Morning Initiation Summary for June 1, 2012

Financial news for BMRN dated on 2012-05-31: BioMarin Pharmaceutical Falls 4% Pre-Market on Offering of 6.5M Shares

Financial news for BMRN dated on 2012-05-31: BioMarin Announces Pricing of Public Offering of Common Stock; 6.5M Shares for \$248.885M

Financial news for BMRN dated on 2012-05-30: BioMarin Pharma Files Common Stock Shelf Registration

Financial news for BMRN dated on 2012-05-30: BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for BMRN dated on 2012-05-15: Top 10 Small Cap ETFs

Financial news for BMRN dated on 2012-05-14: UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

Financial news for BMRN dated on 2012-05-14: Citigroup Maintains BioMarin Pharmaceuticals at Buy, Raises PT from \$45 to \$49

Financial news for BMRN dated on 2012-05-08: BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer

Financial news for BMRN dated on 2012-04-26: BioMarin Pharmaceuticals Reports Q1 EPS \$-0.21 vs \$-0.14 Est; Revenues \$116.6M vs \$118.78M Est

Financial news for BMRN dated on 2012-04-12: UBS Initiates Coverage on BioMarin Pharmaceuticals at Buy, Announces PT of \$43

Financial news for BMRN dated on 2012-03-26: Canaccord Initiates Coverage on BioMarin Pharmaceuticals at Buy, Announces PT of \$43

Financial news for BMRN dated on 2012-03-19: UPDATE: Brean Murray Carret Upgrades BioMarin Pharmaceutical to Buy

Financial news for BMRN dated on 2012-03-19: Benzinga's Top Upgrades

Financial news for BMRN dated on 2012-03-19: Brean Murray Carret & Co. Upgrades BioMarin Pharmaceuticals from Hold to Buy, Maintains PT at \$41

Financial news for BMRN dated on 2012-03-08: BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA

Financial news for BMRN dated on 2012-02-21: BioMarin Announces Chief Financial

Officer Jeffrey Cooper to Leave the Company

Financial news for BMRN dated on 2012-02-16: BioMarin Guides \$255-265M for R&D in 2012

Financial news for BMRN dated on 2012-02-16: BioMarin Pharmaceuticals Reports Q4 EPS \$(0.23) vs \$(0.11) Est; Revenues \$107.85M vs \$115.30M Est

Financial news for BMRN dated on 2012-02-16: BioMarin Initiates Phase 1 Trial for BMN-111 for the Treatment of Achondroplasia

Financial news for BMRN dated on 2012-02-14: BioMarin Pharmaceutical CEO: Expect 2012 Revenues to be Greater than 2011 -CNBC

Financial news for BMRN dated on 2012-02-13: BioMarin Pharmaceuticals Hits 52-Week High of \$38.66

Financial news for BMRN dated on 2012-02-06: BioMarin Pharmaceuticals Hits 52-Week High of \$38.22

Financial news for BMRN dated on 2012-02-03: BioMarin Pharmaceuticals Hits 52-Week High of \$38.13

Financial news for BMRN dated on 2012-02-02: BioMarin Pharmaceuticals Hits 52-Week High of \$37.85

Financial news for BMRN dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for BMRN dated on 2012-01-05: JPMorgan Confab Kicks Off Biotech 2012

Financial news for BMRN dated on 2011-12-19: BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility

Financial news for BMRN dated on 2011-12-09: Stifel Nicolaus Maintains Hold on BioMarin Pharmaceuticals

Financial news for BMRN dated on 2011-12-09: Brean Murray Maintains Hold on BioMarin Pharma After Analyst Day

Financial news for BMRN dated on 2011-11-30: BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority for \$81M

Financial news for BMRN dated on 2011-11-30: Wedbush Maintains Neutral, \$34 Target on BioMarin Pharmaceuticals

Financial news for BMRN dated on 2011-11-29: BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA

Financial news for BMRN dated on 2011-11-28: BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility

Financial news for BMRN dated on 2011-10-28: BioMarin Pharmaceutical Hits New 52-Week High, \$34.85

Financial news for BMRN dated on 2011-10-28: UPDATE: J.P. Morgan Raises PT on BioMarin Pharmaceuticals to \$38

Financial news for BMRN dated on 2011-10-28: JP Morgan Raises PT on BioMarin Pharmaceuticals from \$35 to \$38, Maintains Overweight

Financial news for BMRN dated on 2011-10-27: BioMarin Pharmaceutical Reports Q3 EPS \$(0.16) vs \$(0.10) Est; Revenues \$113.43M vs \$113.28M Est

Financial news for BMRN dated on 2011-10-17: UPDATE: Jefferies Raises PT on BioMarin Pharma to \$38

Financial news for BMRN dated on 2011-10-17: Jefferies Raises PT on BioMarin Pharmaceuticals to \$38

Financial news for BMRN dated on 2011-10-03: Piper Jaffray Overweight on BioMarin Pharmaceutical (BMRN)

Financial news for BMRN dated on 2011-09-28: Notable Call Options Activity in BioMarin Pharmaceutical

Financial news for BMRN dated on 2011-09-28: Notable Call Options Activity in BioMarin Pharmaceutical

Financial news for BMRN dated on 2011-09-28: UPDATE: Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy

Financial news for BMRN dated on 2011-09-28: Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy, PT Raised to \$40

Financial news for BMRN dated on 2011-09-21: UPDATE: Piper Jaffray Raises Price Target On BioMarin Pharmaceuticals to \$43

Financial news for BMRN dated on 2011-09-12: BioMartin Reports \$19.6M Notes Converted Into 1.8M Shares

Financial news for BMRN dated on 2011-08-10: UPDATE: Piper Jaffray Upgrades BioMarin To Overweight

Financial news for BMRN dated on 2011-08-10: Piper Jaffray Upgrades BioMarin To Overweight, Raises PT To \$33

Financial news for BMRN dated on 2011-07-31: Stocks to Watch for Monday 8/01/2011: Fresh 52 Week Highs and Lows

Financial news for BMRN dated on 2011-07-28: Biomarin Pharmaceuticals Reports Q2 EPS \$(0.05) vs \$(0.11) Est; Revenues \$110.63M vs \$105.90M Est

Financial news for BMRN dated on 2011-07-20: Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows

Financial news for BMRN dated on 2011-07-14: BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies

Financial news for BMRN dated on 2011-07-14: Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows

Financial news for BMRN dated on 2011-06-23: BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer for \$48.5M

Financial news for BMRN dated on 2011-06-19: 8 Potential Biotech Acquisition Candidates

Financial news for BMRN dated on 2011-06-19: T. Boone Pickens' 4 Newest Energy Stock Picks

Financial news for BMRN dated on 2011-06-19: Pandora: The Latest Sign of Tech Bubble 2.0

Financial news for BMRN dated on 2011-06-19: 10 Dividend Kings Every Smart Investor Should Own

Financial news for BMRN dated on 2011-06-07: BioMarin Initiates Phase 3 Trial for Amifampridine Phosphate for the Treatment of LEMS

Financial news for BMRN dated on 2011-04-29: J.P. Morgan Maintains Overweight on BioMarin Pharmaceuticals (BMRN)

Financial news for BMRN dated on 2011-04-28: BioMarin Pharma Reports EPS of \$0.14 vs. \$(0.10) Estimate; Revenues \$109.5M vs. \$103.8M Estimate (BMRN)

Financial news for BMRN dated on 2011-04-07: Global Hunter Maintains Neutral on Myriad Genetics (MYGN)

Financial news for BMRN dated on 2011-04-06: Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement

Financial news for BMRN dated on 2011-02-18: BioMarin Spending More Than Expected, Deutsche Bank Downgrades To Hold

Financial news for BMRN dated on 2011-02-18: Deutsche Bank Downgrades BioMarin Pharmaceuticals To Hold, PT Remains \$27

Financial news for BMRN dated on 2011-02-18: Jefferies Raises PT on BioMarin Pharma to \$33 (BMRN)

Financial news for BMRN dated on 2011-02-18: J.P Morgan Comments On BioMarin Pharmaceuticals Following Earnings; Raises PT

Financial news for BMRN dated on 2011-02-18: Piper Jaffray Comments On BioMarin Pharmaceutical Following Earnings Results

Financial news for BMRN dated on 2011-02-18: Jefferies Raises PT On BioMarin

Pharmaceuticals To \$33

Financial news for BMRN dated on 2011-02-18: JP Morgan Raises PT On BioMarin Pharmaceuticals To \$32

Financial news for BMRN dated on 2011-02-17: BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results: Net Loss of \$0.11 Per Share

Financial news for BMRN dated on 2011-02-07: Piper Jaffray Neutral On BioMarin Pharmaceutical (BMRN)

Financial news for BMRN dated on 2011-02-01: BioMarin Initiates Pivotal Phase 3 Trial for GALNS

Financial news for BMRN dated on 2011-01-12: BioMarin Studies Cure for Cancer - Analyst Blog

Financial news for BMRN dated on 2011-01-12: BioMarin Studies Cure for Cancer - Analyst Blog

Financial news for BMRN dated on 2011-01-11: BioMarin Initiates Phase 1/2 Trial for BMN 673

Financial news for BMRN dated on 2010-12-10: Wells Fargo Resumes Coverage On BioMarin With \$23-\$28 Valuation Range

Financial news for BMRN dated on 2010-12-03: Boost for BMRN Pipeline - Analyst Blog

Financial news for BMRN dated on 2010-12-03: Boost for BMRN Pipeline - Analyst Blog

Financial news for BMRN dated on 2010-12-02: Benzinga's Top Downgrades (BMRN, ARO, APWR, BUCY)

Financial news for BMRN dated on 2010-12-02: UBS Downgrades BMRN To Neutral

Financial news for BMRN dated on 2010-12-01: Piper Jaffray On BioMarin Pharmaceuticals

Financial news for BMRN dated on 2010-11-19: The Daily Long and Short Setup

Financial news for BMRN dated on 2010-11-02: In-line Revenues at BioMarin - Analyst Blog

Financial news for BMRN dated on 2010-11-01: Biomarin Pharmaceutical Downgraded to Hold

Financial news for BMRN dated on 2010-10-28: BioMarin Announces Third Quarter 2010 Financial Results: EPS of 1.74

Financial news for BMRN dated on 2010-10-20: J.P. Morgan Reiterates Overweight On BioMarin (BMRN)

Financial news for BMRN dated on 2010-10-19: BioMarin Announces Program for BMN-111

Financial news for BMRN dated on 2010-10-01: Betting on Biotech - Interview with Adam Feuerstein, Senior Columnist and Biotech Analyst of TheStreet.com

Financial news for BMRN dated on 2010-09-13: Oppenheimer's Current Biotech Ratings

Financial news for BMRN dated on 2010-08-31: Good News for BioMarin's Pipeline - Analyst Blog

Financial news for BMRN dated on 2010-08-25: BioMarin Evenly Poised - Analyst Blog

Financial news for BMRN dated on 2010-08-18: BioMarin Acquires Zystor - Analyst Blog

Financial news for BMRN dated on 2010-08-18: BMRN Acquires ZyStor Therapeutics

Financial news for BMRN dated on 2010-08-17: BioMarin to Acquire ZyStor Therapeutics, Inc.

Financial news for BMRN dated on 2010-08-17: BioMarin Initiates Phase 3b Study on Subjects with PKU

Financial news for BMRN dated on 2010-08-03: BMRN Rev Misses, Cuts Outlook - Analyst Blog

Financial news for BMRN dated on 2010-08-03: BioMarin (BMRN) 2Q Results In Line

Financial news for BMRN dated on 2010-08-03: Benzinga's Top Pre-Market NASDAQ Losers (SYKE, BMRN, IVAC, ARMH)

Financial news for BMRN dated on 2010-08-02: BioMarin Pharmaceutical Misses Earnings Estimates (BMRN)

Financial news for BMRN dated on 2010-07-19: Piper Jaffray Lowers Price Targets In Biotech Complex (BMRN, GENZ, GILD, CELG, ALXN, HGSJ)

Financial news for BMRN dated on 2010-06-09: John Tepichin Making Great Trades (BMRN, CIEN, NYX, RSH, TIF)

Financial news for BMRN dated on 2010-04-30: BMRN To Initiate P3 for GALNS in Q4

Financial news for BMRN dated on 2010-04-30: Piper Jaffray Raises BioMarin Pharmaceutical (BMRN) Price Target

Financial news for BMRN dated on 2010-03-25: Benzinga's Volume Movers (TRIT, LULU, GIII, BMRN, CKEC)

Financial news for BMRN dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for BMRN dated on 2010-03-10: Stocks That Created New 52-Week Highs (BGCP, BIIB, BMRN, BJRI, BRCM)

Financial news for BMRN dated on 2010-03-09: Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)

Financial news for BMRN dated on 2010-02-23: BioMarin Pharmaceutical Earnings (BMRN)

Financial news for BMRN dated on 2010-02-08: Benzinga's Top Downgrades (BMRN, AMB, DNB, ARG, HK)

Financial news for BMRN dated on 2010-02-05: BioMarin Pharmaceutical, Inc. (BMRN) One Of Top Picks Of 2010

Financial news for BMRN dated on 2010-01-15: Mid Cap Biotechs May Outperform In 2010

Financial news for BMRN dated on 2009-11-13: BioMarin Says Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme

Financial news for BMRN dated on 2009-11-13: BioMarin Pharmaceutical Inc. Falling On The Genzyme News

Financial news for BMRN dated on 2009-10-29: 5 Stocks with a Change in Guidance (BMRN, HTZ, LTD)

Financial news for BMRN dated on 2009-10-27: BioMarin (BMRN) Acquires Aceras BioMedical Portfolio Company

Financial news for BMRN dated on 2009-10-26: BioMarin Acquires Huxley Pharmaceuticals, Inc.

Financial news for BMRN dated on 2009-09-17: Jim Cramer Would Sell COMS, BMRN, EGLE, HURN, WVE

Financial news for BMRN dated on 2009-08-13: WallStSense.com Fundamental & Technical Coverage of CIEN, AVNR, DRIV, BMRN, CTIC and UMPQ